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Drosophila as a Model for Myosin-Induced Dilated Cardiomyopathy 
  
 
by 
 
 
Adriana Sara Trujillo 
Doctor of Philosophy in Biology 
University of California San Diego, 2020 
San Diego State University, 2020 
Professor Sanford I. Bernstein, Chair 
 
 
 
Dilated cardiomyopathy (DCM) leads to cardiac contractile deficits and pathological 
dilation of the left ventricle, which may result in heart failure. Inherited DCM can be caused by 
mutations in contractile proteins (e.g. myosin). Though myosin DCM mutations are generally 
thought to reduce myosin function, the structural and molecular origins leading to cardiac 
dilation are not well understood. Here, we took advantage of the powerful genetic tools available 
in Drosophila to generate the first fly models of myosin-induced DCM and determine the 
mechanistic basis of disease. The S532P and R369H mutations, located within the actin-binding 
region at residues mutated in DCM patients, were introduced into Drosophila myosin heavy 
 
xvi 
chain. We implemented an integrative approach to determine how these mutations disrupt 
intramolecular interactions and cause biochemical, structural and physiological defects in 
muscles. Given the location of these mutations within known actin binding sites, we 
hypothesized that they cause DCM by disrupting actomyosin interactions, leading to reduced 
myosin motor function and hypo-contractility of muscles.  
To define the exact intramolecular interactions disrupted by the S532P DCM mutation, 
we are using cryo-electron microscopy to solve the structure of the mutant motor domain bound 
to F-actin. Preliminary analyses of negatively stained samples suggest that the S532P mutation 
disrupts the transition from weak to strong actin binding. Biochemical and muscle mechanics 
experiments revealed that the S532P mutation leads to depressed power output by increasing 
the rate of actin detachment and reducing and the rates of actin binding and actin-dependent 
enzymatic activity. Additionally, the R369H mutation reduces maximal actin binding in vitro. Both 
mutations reduce skeletal muscle function, suggesting that these myosin forms are 
underfunctional. S532P mutant hearts exhibit a dilated phenotype, which may compensate for 
reduced myosin function by preserving cardiac output.  
Overall, and in support of our hypothesis, the S532P and R369H mutations impair 
actomyosin interactions and thereby decrease muscle function. These studies provide insight 
into the molecular basis by which contractile deficits induced by mutations of these residues in 
humans lead to compensatory enlargement of the left ventricle. Future work will exploit our fly 
models for drug screening to provide insight into potential therapeutic treatments for human 
patients. 
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Chapter 1: General introduction 
  
 
2 
1.1. Myosin-induced dilated cardiomyopathy 
Dilated cardiomyopathy (DCM) is a heart disease involving weakening of the heart, 
leading to pathological ventricular dilation and wall thinning.1 DCM can be caused by 
environmental and lifestyle factors, as well as genetic factors. Hereditary DCM commonly 
involves point mutations in genes essential for heart function, including myosin.2  
 Myosin II molecules serve as the molecular motor of striated (cardiac and skeletal) 
muscles.3 Striated muscles contain hundreds to thousands of cylindrical myofibrils, each 
composed of numerous repeating sarcomeres as their functional contractile units. The structure 
of the sarcomere contains thick filaments mainly composed of myosin (Fig. 1.1A- blue) and thin 
filaments mainly composed of actin (Fig. 1.1A- red). Fig. 1.1A’ shows an electron micrograph of 
a Drosophila indirect flight muscle sarcomere. The electron-dense boundaries of the 
sarcomeres are called Z-disks. Alpha-actinin crosslinks the barbed (+) ends of the thin filaments 
to the Z-disks. Myosin rods are packed in an antiparallel fashion relative to the center of the 
sarcomere (M-line). The area containing thick filaments is the A-band. The I-bands adjacent to 
the Z-disks contain thin filaments and are devoid of thick filaments. During muscle contraction, 
the thick filaments interact with thin filaments to allow filament sliding and sarcomere shortening, 
causing the I-bands to shorten and the Z-disks to come closer together. This process is 
dependent on ATP hydrolysis by myosin.  
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Figure 1.1- Introduction of sarcomere structure, myosin structure, and the actomyosin 
crossbridge cycle 
A) Illustration of a sarcomere (A) and corresponding transmission electron microscopy (TEM) 
micrograph (A’) in longitudinal orientation in Drosophila indirect flight muscle (IFM) in 2 day-old 
flies. Blue- thick myosin filaments; red- thin actin filaments, M-mitochondrion. B) Illustration of a 
myosin II molecule. The S1 (head) domain contains both the actin binding site and ATP binding 
pockets.  The S2 domain contains a coil-coiled rod. RLC- Regulatory light chain. ELC- Essential 
light chain. C) Steps of the myosin ATPase cycle. Strong binding of myosin (M) to actin (A) 
occurs during the ADP bound state following Pi release, and in the nucleotide-free rigor state.  
 
4 
The structure of the myosin II molecule is shown in Fig. 1.1B. Each myosin II molecule 
contains two myosin heavy chains (MHCs), each with a globular head and an α-helical coiled-
coil rod [reviewed by Geeves and Holmes4]. An assembly of α-helical coiled rods form the 
backbone of the myosin thick filament. The globular portion of the head is the motor domain 
(also known as subfragment-1, S1), which can bind actin and exhibits ATPase activity. The 
actin-binding cleft separates the upper and lower 50 kDa subdomains and is thought to close 
during the transition from weak to strong binding. Mutations causing disruptions in the structure 
of the head domain, including those that interfere with actin binding, can produce severe 
contractile defects.5 Each heavy chain associates with an essential light chain and a regulatory 
light chain at the neck region. The lever arm, which extends from the neck to the base of the 
head, regulates the position of the myosin motor domain as it interacts with the actin filament.  
The interactions between myosin and actin are coupled to the nucleotide state of the 
myosin motor.6,7 In a model depicting the actomyosin crossbridge cycle (Fig. 1.1C), weak 
binding to actin occurs when ATP or the products of ATP hydrolysis (ADP+Pi) are bound, 
whereas strong binding occurs when ADP is bound or in the rigor state (A-M) after ADP 
dissociates. Thus, myosin is strongly attached to actin during the nucleotide-free rigor state until 
ATP binding results in detachment. Subsequent hydrolysis of ATP causes the myosin head to 
reorient, allowing binding to a different actin subunit. The release of Pi and ADP results in a 
rotation of the myosin head relative to the thin filament, causing the lever arm to drag forward 
and actin filaments to slide past myosin filaments towards the middle of the sarcomere. 
DCM mutations in the MYH7 gene encoding human β-cardiac myosin heavy chain (β-
MyHC) often disrupt intramolecular interactions essential for proper protein function and 
decrease contractility.5,8 Myosin functional deficits often result in decreased force generation 
due to altered actomyosin interactions or impaired ATP binding.9,10 Distinct step(s) of the 
ATPase cycle can be altered by different myosin DCM mutations, depending on the mutation 
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location within the motor domain and the nature of the amino acid change.2,8 Initial cardiac 
dilation is thought to compensate for contractile deficits and reduced cardiac output by 
increasing the amount of blood pumped through the heart. However, further dilation can cause 
pathological cardiac remodeling in which the heart walls become thin and weak. This 
pathological dilation can reduce cardiac output and lead to heart failure. In contrast, myosin-
induced hypertrophic cardiomyopathy (HCM), a disease which causes the heart walls to 
become thickened, generally involves increases in myosin function and contractility. Myosin-
induced restrictive cardiomyopathy (RCM), which causes impaired ventricular relaxation, is 
thought to share a common mechanism with HCM, resulting in increased contractility [reviewed 
by Lu et al.11]. Overall, differing effects on cardiac myosin performance can cause distinct 
cardiac remodeling events. We previously explored the mechanistic basis of myosin-induced 
HCM12 and RCM13 using the Drosophila (common fruit fly) model system. Here, we aim to 
generate the first Drosophila models for myosin-induced DCM to better understand how these 
mutations cause the disease. 
1.2. Drosophila as a model for heart disease 
Drosophila is a useful model because organisms are easy to culture, have a short 
generation time, a well-defined life cycle, and are amenable for transgenic manipulation.14 
Furthermore, the availability of balancer chromosomes facilitates the generation of stable lines 
by preventing homologous recombination and allowing for the identification of mutant alleles 
using phenotypic markers. Drosophila are useful as a model for human disease, since there are 
known Drosophila orthologs for 77% of human disease genes.15 Drosophila have proven useful 
for exploring cellular pathways involved in disease and for drug target discovery via high 
throughput screening.16  
Drosophila is an attractive model to determine the mechanistic basis of myosin-induced 
DCM. In contrast to vertebrates, which contain complex multigene myosin families, Drosophila 
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contain a single-copy myosin (Mhc) gene, making it a simple model to study myosin muscle 
diseases (myopathies).17 Drosophila Mhc contains 19 exons, 5 of which are alternatively spliced 
to produce multiple protein isoforms.18 Drosophila serves as an excellent model for expression 
and isolation of myosin from indirect flight muscles (IFMs) of the thorax for biochemical and 
structural studies.19 Additionally, IFMs contain a highly ordered array of myofibrils similar to 
human skeletal muscles and their functional impairment can be readily assessed in vivo by flight 
testing.20  Thus, we exploited the IFM system to define the structural, biochemical, cell 
biological, and functional defects caused by DCM-associated myosin mutations predicted to 
perturb actin binding (see Chapters 2, 3, and 5).  Drosophila is further useful for studying heart 
disease since many genes controlling heart differentiation and function (e.g., the differentiation 
factor Tinman/Nkx 2.5, the contractile protein myosin) in Drosophila are evolutionarily conserved 
[reviewed by Bier and Bodmer21]. The dorsal vessel in Drosophila includes the heart, which is 
composed of a simple tube-like structure located in the abdomen.21 Drosophila heart function 
can be severely perturbed without compromising viability, since flies also utilize a tracheal 
respiration system to deliver oxygen directly to tissues. We further exploited our fly models to 
investigate the cardiac physiological and ultrastructural defects associated with the expression 
of myosin DCM mutations (see Chapters 4 and 5). 
 
1.3 Significance 
Dilated cardiomyopathy (DCM) affects approximately 36 of 100,000 persons in the US.10 
Point mutations in sarcomeric proteins (e.g. myosin) have been suggested to cause familial 
DCM in approximately 10% of cases and are typically inherited in an autosomal dominant 
fashion.5 The molecular mechanisms by which myosin mutations lead to contractile defects and 
pathological remodeling (e.g. cardiac dilation) are not well known. Here, we exploited the 
efficiency of germline transformation in Drosophila and a plethora of techniques implemented by 
our lab and our collaborators to better understand disease mechanisms. We determined how 
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interruptions in interactions important for actin-binding correlate to myosin defects at the 
biochemical level and to overall structural and functional changes in muscles. We also assessed 
whether defects in the Drosophila heart correlate with disease severity observed in humans. 
The development of successful Drosophila models for myosin-based DCM will be useful for 
high-throughput screening to determine if the Drosophila heart dilates in response to other 
myosin mutations found in patients with DCM. Since DCM patients with myosin mutations may 
harbor mutations in other proteins important for muscle function [reviewed by Mestroni and 
Taylor22], an efficient screening system will be highly useful to predict which mutations are 
causative of disease. Overall, our integrative models provide a broad-based understanding of 
the molecular origins and physiological basis of myosin-induced DCM. 
Chapter 1, in full, contains unpublished material coauthored by Trujillo, Adriana S.; 
Bernstein, Sanford I. The dissertation author was the primary investigator and author of this 
chapter. 
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Chapter 2: Determine whether myosin DCM mutation S532P 
interrupts interactions important for actin binding 
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2.1. Introduction 
2.1.1. S532P MYH7 mutation 
There were several criteria for choosing an MYH7 human DCM mutation to model in 
Drosophila. To generate a relevant disease model, we ensured that the residue of interest is 
conserved between MYH7 and Drosophila Mhc. Mutation of a constitutive exon was chosen to 
study the effects of the mutations on different myosin isoforms. We chose a mutation located in 
subfragment-1 (S1) to explore the structural basis of disease via X-ray crystallography or 
electron microscopy. The X-ray crystal structure of the globular S1 domain (PDB ID#: 5W1A) 
has been solved in our lab in collaboration with Dr. Tom Huxford (SDSU), and by other groups 
(23-25). Additionally, the structure of the complex of S1 bound to F-actin has been solved by 
negative staining26 and cryo-electron microscopy.27-29 We were particularly interested in a 
mutation that localizes to an actin binding site, since it is a well-characterized functional region 
of the motor that is essential for contractility. To determine whether findings from our fly models 
correlate to mouse models and the human condition, we sought to model a mutation that was 
previously modeled in mice and well-characterized phenotypically in humans. For these 
reasons, we chose to model the β-MyHC S532P DCM mutation in Drosophila. 
Several DCM patients harboring the S532P mutation have been described.5,9 In a mouse 
model of DCM, animals expressing S532P in α-cardiac MyHC (the major cardiac isoform in 
adult mice) exhibited progressive left ventricular (LV) dilation in heterozygotes and early onset 
cardiac dilation along with contractile deficits in homozygotes, suggesting a DCM-causative and 
gene dose-dependent role of the mutation.30 Genetic testing in patients revealed that the 
mutation is caused by a T→C transition at nucleotide position 1680 of MYH7.5 The location of 
the conserved S532P residue (Fig. 2.1- green residue, boxed inset) is modeled on the crystal 
structure of chicken skeletal muscle myosin II in the post-rigor configuration.25 This structure 
was chosen for modeling due to well-documented binding sites for actin.25,31-33 However, we 
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verified the presence of structurally-conserved regions containing the residue of interest in the 
human β-cardiac myosin heavy chain isoform (β-MyHC, PDB ID#: 4DB1) and Drosophila 
embryonic MHC isoform (PDB ID#: 5W1A) crystal structures. The β-MyHC S532 residue (D. 
melanogaster MHC S531) is located within an actin binding site (red) in an α-helix in the lower 
50-kd conserved subdomain.25 Kamisago et al. predicted that the S532P mutation interrupts the 
α-helical structure and disrupts actin binding.5 Since the S532P mutation is located in a 
structurally conserved actin binding region, we predict that changes in the structure of the 
Drosophila indirect flight muscle isoform (IFI) would result in biochemical alterations in myosin 
function that are relevant to the changes that occur in cardiac tissues. 
 
11 
 
Figure 2.1- The location of the S532P myosin residue within an actin binding region of 
the motor domain. 
The β-MyHC S532 residue (green) was modeled on the crystal structure of chicken skeletal 
muscle myosin II in the post-rigor configuration (PDB ID: 2MYS). Red- actin binding sites. 
Yellow- ATP binding pocket.  
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2.1.2. Hypothesis and goal 
Given the location of the S532 residue within an actin binding region of the motor 
domain, we hypothesized that the S532P mutation interrupts interactions important for actin 
binding. To test this hypothesis, we sought to examine specific structural changes induced by 
this mutation using X-ray crystallography and electron microscopy.  
2.1.3. Introduction to X-ray crystallography and transmission electron 
microscopy 
We initially sought to determine structural changes induced by the mutation using X-ray 
crystallography. This method involves the formation of protein crystals, which contain a highly 
ordered array of protein molecules in a periodic lattice.34 Upon treatment with an X-ray beam, 
diffraction is observed when radiation is scattered by the atoms in the lattice to form a series of 
spots, called reflections. Each reflection represents a wave of electromagnetic radiation, each 
with an associated amplitude and phase. The intensities of the reflections are related to the 
amplitudes of the waves. However, the phase information is lost during data collection, and 
must be calculated experimentally. In molecular replacement, a previously solved structure that 
is predicted to be highly similar to the unknown structure is repositioned to obtain the best 
agreement with the data set. After solving the phase problem, an electron density map is 
generated. Atoms are fit individually into the electron density map to obtain an atomic model. 
Through a series of refinements, the preliminary model is refined against the experimental data 
until there is a high degree of agreement between the data and the model. The generation of a 
protein crystal with good diffraction is often the major hurdle in crystal structure determination.35 
Crystal formation involves the association of protein molecules in three dimensions to form a 
nucleus, followed by the addition of protein molecules in a highly ordered fashion. 
Crystallography involves screening for reservoir solutions that promote crystal nucleation and 
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growth. Precipitants are added to these solutions to draw water away from the protein 
molecules and increase the supersaturation of the system, allowing the protein molecules to 
associate. Salts are often added to enhance protein solubility. Too much supersaturation can 
cause precipitation of the protein and impede nucleation and crystal growth. Alternatively, it can 
cause excessive nucleation and lead to the formation of small microcrystals that are not 
amenable for data collection. If crystal drops remain undersaturated after extensive incubation, 
nucleation may not occur. Under ideal conditions following nucleation, the free protein 
concentration in the drop is lowered, allowing crystal growth but not permitting further nucleation 
events. Thus, finding a condition that promotes growth of a single large crystal is challenging, 
and can require extensive screening. 
Transmission electron microscopy (TEM) involves placing a sample under a high 
vacuum, and running a focused electron beam through the sample, so that the electrons interact 
with it.36 The transmitted signal is focused, magnified, and the signal is converted to photons. 
The resulting image shows the electron density of the sample. Single particle analysis is a 
common TEM-based approach for structure determination.37 It involves collecting large data 
sets, selecting particles of interest, and performing 2-dimensional and 3-dimensional alignments 
to reconstruct a model. The maximum resolution achieved by this approach is variable, and 
depends on the method employed for sample preparation, data collection, and model building. 
In negative staining TEM, an electron dense stain is used to coat the surface and surroundings 
of the sample. Negative staining structures generally have a maximum resolution of 20 Å, which 
is limited by the grain size of the staining reagent.38 Cryo-electron microscopy, which involves 
freezing samples under their native state to protect against damage from the electron beam, 
can typically achieve resolutions of 6-10 Å, with some structures reaching near atomic 
resolution.39,40  
Though the resolution can be limited compared to the atomic-level resolution obtained 
via X-ray crystallography, TEM is an attractive option for myosin structure determination. TEM 
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can be used to determine the structure of the actomyosin complex, as attempts to crystallize the 
complex have not been successful.41 This is particularly advantageous for the S532P mutation, 
which resides in the actin-binding interface of myosin. Unlike TEM, X-ray crystallography 
requires the extensive screening for crystals with high resolution diffraction. Each protein form 
can crystallize under distinct conditions, making it challenging to make structural comparisons 
between the mutants and controls. To form crystals, protein samples are often treated with 
precipitants, harsh detergents, or additives that are not normal components of the myofibril, 
making it unknown whether the proteins crystallize in a conformation that is biologically 
relevant.35 In contrast, TEM involves fixing proteins in solutions that have been optimized for 
protein stability and activity. For these reasons, and because adequately diffracting crystals 
were not obtained upon screening, we sought to use a TEM-based approach to form the 
actomyosin complex and determine the structural basis of disease. 
2.2. Materials and Methods 
2.2.1. Generation of a mutant His-tagged myosin line 
Myosin quantities sufficient for biochemical studies have been isolated from 
microdissected IFMs due to high expression levels of myosin and large size relative to other 
Drosophila muscles.42,43 However, milligram quantities of protein are essential for effective 
crystallization screening, which is difficult to achieve by primary dissection. To bypass the need 
for dissection, our lab expressed, isolated and purified His-tagged embryonic myosin from IFMs 
of >20000 homogenized flies per preparation using a series of salt-based extractions and Ni-
column chromatography.19 In conjunction with Dr. Tom Huxford (SDSU), our group used the 
purified embryonic myosin protein to solve the first X-ray crystal structure of an insect muscle 
myosin (PDB ID#:5W1A). The IFM-specific myosin isoform (IFI) has also been crystallized and 
had its structure determined (manuscript in preparation). For the current study, we generated a 
fly line expressing a His-tagged mutant version of IFI for structural studies. 
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To generate a mutant construct, we utilized a pAttB 6HisIFI plasmid previously produced 
by our lab, which contains the IFM-specific Actin-88F promoter, an amino-terminal His-tag, a 
tobacco etch virus (TEV) protease recognition site (for removal of the His-tag), cDNA encoding 
the IFI motor domain, as well as genomic DNA encoding MHC exons 12-19 along with their 
affiliated introns and polyadenylation sites. The cloning strategy for the S532P construct is 
shown in Fig. 2.2. For the first two steps, subclones containing Mhc exon 10 were generated 
from the larger plasmid. Oligonucleotide-directed mutagenesis was performed (QuikChange kit, 
Stratagene) to change the codon in Drosophila Mhc that corresponds to the MYH7 S532P 
nucleotide transition. The following forward (+) and the reverse (-) primers were used: 
     S532P (+): 5'-TCTTCCTCCAGGATGGGCAAGATACCCATGGTG-3’ 
     S532P (-): 5'-CACCATGGGTATCTTGCCCATCCTGGAGGAAGA-3'  
The mutated exon was sequenced for confirmation and inserted into a larger cloning 
intermediate. The entire construct was removed and ligated into a pAttB vector containing a 
miniwhite (w+) selectable eye color marker that restores eye color in a white-eyed genetic 
background, as well as PhiC31 integrase AttB recognition sites. The final clone was purified 
using the QIAfilter Plasmid Maxi Kit (Qiagen Inc.) and sequenced for verification by Eton 
Bioscience. Targeted insertion was performed by Bestgene Inc. using the PhiC31-mediated 
transgenesis system.44 One transgenic line containing a third chromosome targeted insert was 
produced. 
  
 
16 
 
Figure 2.2- Cloning scheme for the 6HisIFI S532P construct 
The sequential steps of restriction enzyme (RE) digestion and ligation are shown by the blue 
arrows. Each insert generated by RE digestion of the parent vector is shown in red, along with 
RE cut sites. Site-directed mutagenesis (black arrow) was performed to change the encoded 
serine residue to a proline residue at the 531st amino acid coding position of Drosophila Mhc 
(corresponding to position 532 in human MYH7). The mutant construct was ligated into a pAttB 
vector for targeted insertion by Bestgene, Inc using the PhiC31 transgenesis system. 
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Transgenic flies were crossed into a Mhc10 background that is null for endogenous 
myosin in IFMs.45 Myosin protein levels are expressed at ~78% relative to wild-type yw flies in 
upper thoraces, as determined by SDS-PAGE and densitometry analysis.46 RT-PCR was 
employed to verify that the Mhc transcripts produced by this line contain the appropriate 
nucleotide transition. For this, RNA was isolated from 2 day-old upper thoraces using the 
RNeasy kit by Qiagen, Inc. The Protoscript cDNA synthesis kit was employed to generate 
cDNAs, using 500 ng RNA and 100 ng of the specific reverse (-) primer shown below. The 
following primers were used for PCR amplification: 
(+) 5’-TCTGGATACCCAGCAGAAGCGT-3’ 
(-) 5’-CAGCTGGTGCATGACCAAGTGGGC-3’ 
PCR was performed using 3 μL cDNA and 200 ng of each forward and reverse primer, 
under the following conditions: 120 sec at 98° C, then 30 cycles of: 20 sec at 98° C, 30 sec at 
55° C and 2 min at 68° C. RT-PCR products were sequenced by Eton Bioscience.  
2.2.2. Protein purification 
Bulk S1 was purified from His-tagged flies using a procedure modified from Caldwell et al19:      
1) Clarifying the supernatant and myosin extraction: Adults (<1 day-old) were collected 
daily, flash frozen using liquid nitrogen, and stored at -80°C. A total of 36 grams of flies 
was divided between two tubes and homogenized (OMNI International Homogenizer and 
10 mm stainless probe) in a low salt homogenization buffer [HB, 0.5 % Triton X-100, 
Roche complete protease inhibitor cocktail tablets (1 tablet / 50 mL solution), 12.5% 
sucrose, 40 mM NaCl, 10 mM imidazole-Cl, 2 mM MgCl2, 0.2 mM EGTA, and 1 mM 
DTT, at pH 7.2]. The charged amino acid residues of the myosin rod allow precipitation 
or solubilization of myosin in solutions of low or high ionic strength, respectively.47 Prior 
to solubilization of myosin, a series of centrifugation steps (Beckman Ti-45 rotor, 40,000 
RPM, 1.5 hours each, 4°C) were performed to clarify the soluble portion of the 
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homogenate. The supernatants were discarded following each centrifugation. Following 
the first two centrifugations, the pellets containing the insoluble myosin were 
homogenized in HB. After the third centrifugation step, the pellets were homogenized in 
high-salt myosin extraction buffer (MEB, 500 mM NaCl, 20 mM sodium phosphate 
buffer, 20 mM imidazole-Cl, pH 7.2), sonicated with 50 brief pulses at setting 5, 50% 
duty cycle (Fisher Scientific Sonic Dismembrator Model 100, micro tip), and incubated 
for 30 minutes on ice. Following centrifugation (Beckman Ti-45 rotor, 40,000 RPM, 40 
minutes, 4°C), the pellets containing the exoskeleton and cellular debris were discarded. 
The soluble portions were diluted with a no salt solution to 75 mM NaCl, incubated for 4 
hours on ice to precipitate myosin, and centrifuged (Beckman Ti-45 rotor, 40,000 RPM, 
40 minutes, 4°C). The pellets were resuspended in 60 mL MEB (OMNI International 
Homogenizer with plastic tip) and the extracted myosin was filtered and further diluted 
with 390 mL MEB.  
2) Ni column chromatography: His-tagged myosin was purified using Ni-affinity 
chromatography (HisTrap HP 5 mL column and ÄKTA pure system by GE Life 
Sciences). Following sample binding, the Ni column was washed with 30 mL MEB, and 
the sample was eluted in 30 mL elution buffer (500 mM NaCl, 20 mM sodium phosphate 
buffer, 250 mM imidazole-Cl, pH 7.4). His-tagged myosin was collected in 2 x 2 mL peak 
fractions, and myosin was precipitated by diluting with a no salt solution to 94 mM NaCl. 
3) Purification of myosin motor domain (S1): Precipitated myosin was centrifuged 
(Beckman TLA-100.3 rotor, 68,000 RPM, 50 minutes, 4°C), and pellets were 
resuspended in digestion buffer (120 mM NaCl, 20 mM NaPi, 1 mM EDTA, 4 mM DTT, 
pH 7.0). The S1 fragment was clipped using α-chymotrypsin (Worthington Biochemical 
Corp., 0.18 mg/mL per 67.8 activity units, 6 minutes, 20°C), which was previously shown 
to also remove the His-tag at the TEV cut site.19 To quench the reaction, 
phenylmethylsulfonyl fluoride was added to a final concentration of 1.50 mM. Samples 
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were centrifuged (Beckman TLA-100.3 rotor, 68,000 RPM, 50 minutes, 4°C) to remove 
insoluble rod fragments and uncut myosin from the soluble S1 fraction. To further purify 
S1, size exclusion chromatography was performed using the ÄKTA Pure system with a 
16/600 column packed with Superdex 200. A centrifugal filter (Amicon Ultra-4 mL 10,000 
MWCO) was used to concentrate peak S1 fractions to 2-6 mg/mL. 
2.2.3. X-ray crystallography screening 
A TTP Labtech Mosquito robot was employed to facilitate accurate and precise pipetting 
of small 100 nL sample volumes in a high-throughput fashion. Crystallization trials were initiated 
using reservoir conditions similar to those employed by our lab to crystallize non-mutant S1 in 
the presence of ADP. This did not result in successful crystal formation. Commercially available 
screens were then used to screen numerous (>5000) broad conditions with different nucleotides 
(ADP, the non-hydrolyzable ATP analog AMP-PNP, apo). For this, the Mosquito was employed 
to generate 200 nL sitting drops using 1:1 drop ratios of protein to reservoir solutions from 
Hampton Research crystal screens (Cat. No. HR2-130, HR2-139, HR2-134) or Microlytic 
Crystallization Screens (Cat. No. MCSG-1, MCSG-2, MCSG-3, MGSG-4). Trays were sealed 
and incubated at 4°C or 20°C, then monitored over several months for crystal growth using a 
Formulatrix Rock Imager. Several of the successful crystallization solutions were optimized to 
generate additional crystals amenable in size (>30 micron) and shape (3-dimensional) for data 
collection. Protein and precipitant concentrations were adjusted to promote fewer nucleation 
events in the drops, leading to the formation of fewer larger crystals as opposed to numerous 
smaller crystals. Further optimization trials involved altering the pH, incubation temperature, 
precipitant type and concentration, buffers, additives (i.e. salts, amino acids, reducing agents), 
and the physical method of setting up the crystal drop. A total of 137 3-dimensional (3D) crystals 
were treated with a cryoprotectant solution (containing the crystallization solution along with 
10% glycerol or ethylene glycol) and frozen in liquid nitrogen. Crystals were tested for diffraction 
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remotely at the Stanford Synchrotron Radiation Lightsource (SSRL) or the Advanced Light 
Source (ALS) at Berkeley.  
2.2.4. Negative staining of actomyosin 
To determine if the S532P mutation disrupts interactions important for strong binding to 
actin, we sought to examine the actomyosin complex under rigor conditions (without ATP). In 
preparation for negative staining, over 80 experimental trials were performed to optimize 
complex formation and sample staining. A variety of parameters were adjusted, including 
protein sample preparation, protein concentrations and ratios, pH buffer, salt concentration, 
staining conditions, and the physical methods of sample attachment to TEM grids.  
The following procedure was used ultimately for sample preparation and data collection: 
F-actin (30 μM) was polymerized from frozen G-actin stocks by adding one volume of 10x actin 
polymerization buffer (50 mM Tris-Cl, pH 8, 0.5 M KCl, 20 mM MgCl2, 10 mM ATP) to nine 
volumes of G-actin. To remove ATP and soluble G-actin, a total of 25 μL of 30 μM F-actin was 
centrifuged (Beckman TLA-100 rotor, 78,000 RPM, 12 minutes, 4°C), and the pellet was 
resuspended in 24 μL of a low salt experimental buffer (75 mM KCl, 5 mM HEPES, 1 mM 
MgCl2, 10 mM DTT, pH 7.0). To catalyze the hydrolysis of residual ATP, a total of 1 μL of 
apyrase (New England Biolabs, 500 U/mL) was added for a final concentration of 20 U/mL. F-
actin was incubated at 30°C for 5 minutes, then placed on ice. S1 was diluted to 8 μM for 
control S1 or 10 μM for S532P S1 in the 75 mM KCl buffer. Lower concentrations of control S1 
relative to S532P S1 were used for complex formation to reduce the over-decoration and 
extreme bundling of decorated filaments observed in control samples. Re-purified F-actin and 
S1 were mixed in the 75 mM KCl buffer at a final concentration of 3 μM F-actin and 1.9 μM 
control S1 or 2.4 μM S532P S1. A salt concentration of 75 mM KCl was chosen for complex 
formation, since lower salt concentrations had a detrimental effect on S1 solubility, while high 
salt concentrations disrupted complex formation. HEPES was chosen as a pH buffer, since it 
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was observed to be less reactive than phosphate buffer or MOPS in precipitating the uranyl 
acetate (UA) staining reagent. Samples were incubated on ice for 10 minutes and centrifuged 
(Beckman TLA-100 rotor, 78,000 RPM, 12 minutes, 4°C). Pellets were resuspended in 2.5 μL of 
a 10 mM KCl buffer (10 mM KCl, 5 mM HEPES, 1 mM MgCl2, 10 mM DTT, pH 7.0). The entire 
2.5 μL sample was attached to a carbon-coated, plasma treated grid for 1 minute. Excess 
sample was blotted, and a thin layer of sample was left on the grid. For negative staining, the 
grid was stained with 10 μL 2% UA for 1 minute, washed in 30 μL HPLC H2O, and immediately 
blotted to dry. For cryopreserved samples, unstained samples were attached to a 
Quantifoil® Holey Carbon Film grid, and excess sample was blotted. Grids were plunged in liquid 
ethane and then stored in liquid nitrogen for future use. Cryopreserved samples were imaged on 
a Titan Krios microscope (FEI) equipped with a Falcon II direct electron detector, and a Tecnai 
TEM equipped with a 4k x 4k pixel CCD camera (SBP MDI). Negatively stained samples were 
imaged using a 120 kV Tecnai 12 TEM equipped with a CCD camera (SDSU), which confirmed 
the successful formation of S1-bound decorated actin filaments. For structural determination of 
negatively stained samples, images were recaptured on Kodak film using a 120 kV Tecnai 12 
TEM (Sanford Burnham Prebys MDI), at a magnification of 52,000, and defocus of 1.5 μm. Film 
negatives were scanned using a Photoscan scanner (Zeiss-Intergraph). A total of >2,900 
particles were selected from negatives using Boxer from the Eman software package.48  
Individual 2D particle images were grouped into 69 2D class averages using the Sphire cryo-EM 
software suite.49 
2.3. Results 
2.3.1. Purification of bulk myosin S1 
Flies expressing His-tagged mutant or wild-type myosin were homogenized, and the 
soluble portion of the homogenate was clarified via a series of centrifugation steps. Full-length 
myosin was extracted in a 500 mM NaCl solution (Fig. 2.3: Lane 2). Following Ni column 
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chromatography, the eluted fractions contained His-tagged myosin along with a 70 kD non-
specific binding protein “NS” (Fig. 2.3: Lane 6). Purified myosin was precipitated in a 94 mM 
NaCl solution, and the insoluble fraction was resuspended in digestion buffer (Fig. 2.3: Lanes 7-
9). Full length myosin was subjected to proteolysis by chymotrypsin to produce the S1 and rod 
fragments (Fig. 2.3: Lanes 10-12). S1 was further purified using size-exclusion chromatography 
(Fig. 2.3: Lane 14). Overall, our expression and purification system produced highly 
concentrated S1 (approximately 1 mg at 2-6 mg/mL) suitable for structural determination. 
2.3.2. X-ray crystallography trials 
Commercially available broad-based screens were employed to determine conditions 
that produce S1 protein crystals. Numerous conditions were attempted, including broad 
screening with different nucleotides (ADP, AMP-PNP, apo) and optimization based on previous 
hits. Several of the initial crystallization hits produced crystals unsuitable for data collection, 
generally due to their 2-dimensional (2D) shape or small size. Thus, the solutions that produced 
these crystals were optimized to generate additional crystals amenable for data collection. A 
total of 137 3-dimensional (3D) crystals were tested for diffraction remotely at the Stanford 
Synchrotron Radiation Lightsource (SSRL) and the Advanced Light Source (ALS) at Berkeley. 
Several crystals containing S532P S1 yielded diffraction (maximum resolution of 6.4 Å) (Table 
2.1 and Fig. 2.4: A-B). 
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Figure 2.3- Bulk purification of myosin S1 from homogenized His-tagged flies 
Protein samples were resolved using 10% SDS-PAGE. Sample lanes: 1) Bio-Rad Precision 
Plus ladder Cat #161-0375, 2) High-salt extraction after sonication contains full-length myosin, 
3) High-salt extraction buffer after removal of exoskeleton and cellular debris contains full-length 
myosin, 4) Ni column flow-through, 5) Ni column wash, 6) Ni column eluate contains full-length 
myosin and non-specific Ni-binding protein (NS), 7-9) Low-salt precipitate containing myosin 
solubilized in digestion buffer, 10-12) Post-proteolysis containing rod, S1 and uncut myosin, 13) 
Insoluble fraction containing rod and uncut myosin, 14) Purified concentrated S1. 
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Table 2.1- X-ray diffraction of S532P S1 crystals 
A total of 137 protein crystals containing S532P S1 were remotely tested for diffraction at the 
Stanford Synchrotron Radiation Lightsource (SSRL) at Stanford and the Advanced Light Source 
(ALS) at Berkeley. The crystallization solutions and protein concentrations that yielded 
diffraction-quality crystals are shown. Corresponding cryoprotectant solutions and resolutions of 
diffraction are listed. For all conditions, S532P S1 was mixed with 2 mM AMP-PNP or 2 mM 
ADP and 2 mM MgCl2 in a sitting well plate using a drop volume of 200 nL and a drop ratio of 
1:1 (protein : crystallization solution), and incubated at 20°C. 
  
Crystallization 
solution 
Protein 
concentration 
Cryoprotectant 
solution 
Nucleotide Resolution of 
diffraction 
Hampton Research 
Peg Ion, well D4 (0.2 
M sodium phosphate 
dibasic dihydrate, 
20% w/v polyethylene 
glycol 3,350) 
5 mg/mL 0.2 M sodium 
phosphate 
dibasic 
dihydrate, 20% 
w/v 
polyethylene 
glycol 3,350, 
10% ethylene 
glycol 
ADP 6.4 Å 
Hampton Research 
Index, well G9 (0.2 M 
ammonium acetate, 
0.1 M tris pH 8.5, 25% 
polyethylene glycol 
3,350) 
6 mg/mL 0.2 M 
ammonium 
acetate, 0.1 M 
tris pH 8.5, 25% 
polyethylene 
glycol 3,350, 
10% ethylene 
glycol 
ADP 7.5 Å 
Hampton Research 
Peg Ion, well F10 (0.2 
M ammonium citrate 
tribasic, pH 7.0, 20% 
w/v polyethylene 
glycol 3,350) 
6 mg/mL 0.16 M 
ammonium 
citrate tribasic, 
pH 7.0, 16% 
w/v 
polyethylene 
glycol 3,350, 
10% ethylene 
glycol 
ADP 8.0 Å 
Hampton Research 
Index, well H8 (0.1M 
magnesium formate 
dihydrate, 15% w/v 
polyethylene glycol 
3,350) x 3 crystals 
tested 
3 mg/mL 0.1M 
magnesium 
formate 
dihydrate, 20% 
w/v 
polyethylene 
glycol 3,350, 
10% ethylene 
glycol 
AMP-PNP 16-20 Å 
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Figure 2.4- X-ray diffraction of a 3-dimensional crystal containing S532P S1 
A) A 75 μm crystal was obtained using the following crystallization solution: Hampton Research 
Peg Ion, well D4 (0.2 M sodium phosphate dibasic dihydrate, 20% w/v polyethylene glycol 
3,350) mixed with 5 mg/mL S1, 2 mM ADP, and 2 mM MgCl2 in a sitting well plate using a drop 
volume of 200 nL and a drop ratio of 1:1 (protein : crystallization solution). B) Diffraction of 6.4 Å 
was observed remotely at the Advanced Light Source (ALS) at Berkeley. 
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2.3.3. Transmission electron microscopy of S532P actomyosin 
Due to limited success in obtaining crystals adequate for structural determination, we 
initiated a collaboration with Drs. Dorit Hanein and Niels Volkmann (Sanford Burnham Prebys 
Medical Research Institute) to study the structural basis of S532P dysfunction using 
transmission electron microscopy (TEM). We successfully formed protein complexes containing 
wild-type or S532P S1-decorated F-actin, and assessed complex formation using negative 
staining (NS) and TEM (Fig. 2.5). The binding of S1 to F-actin is unidirectional due to the 
polarity of the actin filaments, which produces a characteristic arrowhead pattern. Each side of 
the arrowhead is composed of an individual S1 monomer. Overall, our methods produce grids 
suitable for structural determination in areas where bound S1 monomers can be clearly resolved 
(Fig. 2.5). However, the majority of grid surfaces contain areas inadequate for data collection. 
Decorated filaments were frequently observed in bundles (Fig. 2.6A and 2.6F). The degree of 
decoration was also variable, with some filaments over-decorated and some under-decorated 
(Fig. 2.6A). The staining patterns were inconsistent throughout the grids, with some areas 
overstained (Fig. 2.6B and 2.6E) and some areas understained (Fig. 2.6C). Additionally, the 
mixture of excess sample buffer with the UA stain formed crystalline deposits on the grid (Fig. 
2.6D-E).  Thus, a blotting step was performed to remove excess buffer from the grid prior to 
staining. This step was performed with caution, leaving a thin wet layer of sample on the grid to 
prevent it from drying out. 
As a preliminary structural assessment, we compared the actomyosin structures of 
samples containing S532P or control S1. Fig. 2.7A is a schematic representation of the 
structural changes associated with the transition from weak to strong actomyosin binding. In the 
rigor conformation, the myosin lever arm is rotated to a position closer to the actin filament (Fig. 
2.7A: red).50 Given that the protein complex was formed under rigor conditions in the absence of 
nucleotide, the myosin heads were expected to adopt the rigor conformation in control samples. 
 
27 
The structures of control (Fig. 2.7B: blue) and S532P (Fig. 2.7B: red) actomyosin were 
superimposed for comparison. For control S1 bound to F-actin, the myosin lever arm appears to 
adopt a rigor position more closely aligned with F-actin. The lever arm sticks out further in the 
S532P mutant relative to the actin filament, resembling a weak actin binding state. Overall, the 
S532P mutation appears to disrupt the transition from weak to strong actin binding. However, it 
is possible that effects of the angular orientation of the particles contribute to the differences 
observed in the mutant structure. 
We are currently performing cryo-EM with single particle analysis to solve the mutant 
and control structures in a quantitative manner that incorporates images of the particles from 
various angular orientations. For this, we sought to solve low-resolution structures obtained from 
negatively stained samples as initial models for cryo-electron microscopy structural 
determination. Images from negatively stained samples of control or mutant myosin bound to F-
actin were captured on film and digitized with a high-resolution scanner. Thousands of single 
bound S1 monomers were manually selected using the Boxer of Eman software package48 to 
generate input images for software reconstruction. Each input image is a 2D rotational view of 
the 3D structure. Individual 2D images were grouped into 69 2D class averages for S532P S1 
bound to F-actin (Fig. 2.8A) using the Sphire cryo-EM software suite.49 Eventually, we will 
employ the Relion software package51 to perform a 2D Fourier transform of the 2D classes and 
generate a 3D model in Fourier space. A Fourier inversion will subsequently be performed by 
the software to obtain a 3D low-resolution map of the structure. Recently, we collected ~4000 
images of cryopreserved S532P S1-decorated F-actin for high-resolution structural 
determination. A representative micrograph is shown in Fig. 2.8B. Though some decorated 
filaments appear bundled (arrows) or underdecorated (asterisk), single bound particles can be 
resolved in a majority of grid surfaces. Overall, we expect these efforts to produce high-
resolution cryo-EM structures. 
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Figure 2.5- Transmission electron microscopy micrograph of negatively stained myosin 
S1-decorated F-actin 
Scale bar, 100 nm. 
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Figure 2.6- Transmission electron microscopy micrographs showing representative 
images of negatively stained actomyosin grids  
Various challenges were encountered during sample preparation and data collection: A) 
Bundling and overdecoration of filaments (white arrow) as well as undecorated filaments (black 
arrow), B) Overstained background, C) Understained background, D) Thick layer of uranyl 
acetate crystalline deposit (asterisk), E) Uranyl layer crystalline deposit and heavy background 
staining, and F) Excessive bundling of decorated filaments (arrowheads). Scale bars, 0.1 µm for 
panels A-E, 2 µm for panel F. 
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Figure 2.7- Preliminary structural analysis of negatively stained S532P S1-decorated F-
actin 
A) Schematic representation of the transition of weak to strong actomyosin binding. Left- The 
myosin motor domain (blue) is weakly bound to F-actin (grey) in a non-force generating state 
with ADP and inorganic phosphate (Pi) attached. Right- Following the release of Pi and ADP, 
the motor domain (blue) is strongly bound to F-actin (grey) in the rigor conformation. In this 
conformation, the lever arm (red), which extends to the myosin neck region, is rotated to a 
position closer to the actin filament. B) TEM micrographs of negatively stained S532P and 
control myosin S1 bound to F-actin. Actomyosin structures were digitally colorized and overlaid 
for comparison. F-actin imaged in the absence of S1 is shown as a control. 
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Figure 2.8- Structure determination of S532P S1 bound to F-actin 
A) TEM samples of negatively stained S532P or control S1 bound to F-actin were used for initial 
structural modeling. Images were captured on film and digitized. Single bound particles were 
manually selected and subjected to 2D class averaging using Sphire.49 Images of the 69 2D-
class averages obtained for S532P S1 bound to F-actin are shown. B) A representative TEM 
micrograph of a cryopreserved sample of S532P myosin S1 bound to F-actin. Arrows- Bundled 
decorated filaments. Asterisk- Undecorated filament. 
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2.4. Discussion 
We performed X-ray crystallography and cryo-electron microscopy (cryo-EM) 
experiments to probe the structural effects of the S532P myosin dilated cardiomyopathy (DCM) 
mutation, which is located in an α-helix within an actin-binding helix-loop-helix motif of the L50 
subdomain.30 We hypothesized that a proline substitution at the S532 residue disrupts 
intramolecular interactions at the L50 subdomain that are important for actin binding, rendering 
the S532P myosin form underfunctional at the biochemical and whole tissue levels. This is in 
concordance with the results reported in chapters 3 and 4, where we found that the S532P 
mutation impairs actomyosin interactions and reduces actin-stimulated ATPase activity, 
resulting in reduced skeletal muscle function and cardiac dilation. 
To understand the potential function of the mutant S532 residue, it is important to focus 
on the known role of the L50 subdomain in which it is located and its interaction with actin. 
During the myosin ATPase cycle, actin binding promotes the release of the products of ATP 
hydrolysis, which is coupled to the lever arm movements referred to as the powerstroke 
steps.7,52,53 Previous cryo-EM reports suggest that the L50 subdomain is involved in the initial 
weak binding to actin. Structural assessment of the state in which myosin-ADP-Pi is weakly 
bound to actin is challenging due to its instability and short lifetime.50 Thus, Fujii et al.50 
compared the cryo-EM structure of mammalian skeletal muscle myosin S1 bound to F-actin in 
rigor with the crystal structure of skeletal muscle myosin II in post-rigor.25 In the post-rigor state, 
myosin is weakly bound to actin when actin is present. The helix-loop-helix structural element of 
L50 subdomain forms hydrophobic interactions with two adjacent actin subunits in post-rigor. 
Loop 2, located between the U50 and L50 subdomains, forms electrostatic interactions with 
actin during the weakly bound ADP+Pi state, and is predicted to act as a tether to allow a 
rotation of the U50 subdomain during the transition from the weak to strong actin binding states. 
The crystal structure of chicken skeletal muscle myosin S1 in post-rigor25 was incorporated into 
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the cryo-EM structure of S1-decorated F-actin in rigor by Holmes et al.52 The L50 subdomain 
interacts with F-actin when myosin is weakly bound to actin. In that state, the binding cleft is 
open.  
In contrast to the L50 subdomain, the U50 subdomain does not interact with actin during 
initial weak actin binding. Following the rotation of the U50 subdomain, additional contacts are 
formed between the U50 subdomain and actin to stabilize the rigor conformation. Behrmann et 
al. compared the cryo-EM structure of actin-tropomyosin-myosin in rigor with the X-ray crystal 
structure of myoE with ADP-VO4 bound in the pre-powerstroke state54 and revealed that the 
L50 subdomain shows little structural difference between weakly-bound and strongly-bound 
states.55 The authors suppose that that myosin initially binds actin at the L50 subdomain, and 
that its contacts with actin are mainly hydrophobic in nature. Since proline is characterized as a 
potent α-helix breaking residue56, we predict that the S532P mutation interrupts hydrophobic 
interactions between the helix-loop-helix motif and actin, which may destabilize the weakly 
bound ADP+Pi state. 
The cryo-EM structures of actomyosin in rigor reported by Holmes et al.52, Behrmann et 
al.55, and Fujii et al.50 suggest that the U50 rotates 15-20 degrees clockwise in response to 
weak actin binding to form additional contacts between the U50 and actin, which closes the 
actin binding cleft and stabilizes the rigor conformation. These contacts are mainly electrostatic 
in nature, and include the binding of the loop 4, the CM loop, and helix W of myosin to the SD1 
and SD3 subunits of one of the actin monomers.55 Loop 3 is bound to the SD1 of the next lower 
pitch helix actin.55 The hydrophobic interactions between the helix-loop-helix motif of L50 and 
actin are thought to serve as a hinge for rotation.52 Overall, these data suggest that the L50 
subdomain plays a role in the structural transition from the weakly bound state to rigor by 
stabilizing interactions with actin to close the binding cleft. Since the S532P mutation is located 
within the helix-loop-helix motif, we predict that it destabilizes interactions that are important for 
the transition to the rigor state. 
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In order to understand how structural changes at the actin binding subdomain induced 
by the S532P mutation reduce myosin function, the communication pathway from the L50 
subdomain to the nucleotide binding pocket must be taken into consideration. The enhancement 
of ATPase activity in response to actin binding has been documented in biochemical and 
kinetics studies.7,57,58 Conformational changes at the actomyosin interface are communicated to 
the nucleotide binding pocket via the transducer subdomain, which includes the last 4 strands of 
a central β-sheet and associated surface loops.59 In response to actin binding, the central β-
sheet becomes distorted.52,55,60 This results in compression of the N-terminal subdomain, which 
is relaxed upon dissociation of Pi.55 In the rigor structures, closure of the binding cleft is 
associated with the opening of the nucleotide binding pocket, suggesting that actin binding 
promotes the release of the products of ATP hydrolysis (Pi and ADP).50,52,55 The X-ray crystal 
structure of chicken skeletal muscle myosin S1 showed that the nucleotide binding pocket 
contains a P-loop with switch 1 and switch 2 elements that gate ATP and the products of 
hydrolysis.25 During the transition from weak binding to rigor, movement of switch 1 and switch 2 
into an open position promotes the release of Pi and ADP from the nucleotide binding 
pocket.50,52,55 Subsequent rotation of the N-terminal and converter subdomains are coupled to 
the lever arm swing which is the powerstroke that yields force generation. 
Our results suggest that the communication pathway that enhances ATPase activity in 
response to actin binding is disrupted by the S532P myosin mutation. In chapter 3, we report 
that actin-stimulated Mg-ATPase activity is reduced in S532P myosin compared to controls, 
while basal Mg-ATPase activity (enzymatic activity in the absence of actin) is unaffected by the 
mutation. Moreover, muscle mechanics of isolated indirect flight muscles and skeletal muscle 
functional tests revealed diminished contractile performance, suggesting that the S532P myosin 
form is under-functional. Our structural work explores whether reductions in actin-activated 
ATPase activity and contractile function of S532P myosin are linked to impaired actomyosin 
interactions. 
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Successful structural studies using crystallization screening and cryo-EM experiments 
are dependent upon milligram quantities of protein, which is difficult to obtain by primary 
dissection. To obviate this difficulty, we developed His-tagged lines expressing the S532P DCM 
myosin mutation in IFMs and obtained bulk quantities of protein from homogenized flash-frozen 
whole flies. Following Ni column chromatography, full length myosin was subjected to 
proteolysis by chymotrypsin, and the subfragment-1 (S1) was purified using size exclusion 
chromatography.19 This yielded approximately 1 mg of purified S1 per preparation, making 
Drosophila a good source of purified myosin for structural analyses. 
Protein molecules must arrange in a highly ordered array to produce a diffraction quality 
crystal.34 The resolution of diffraction from S532P S1 crystals was not adequate for structure 
determination. Thus, it is possible that the mutation affects the ordered packing of protein 
molecules by disrupting intramolecular interactions within the helix-loop-helix motif of the actin 
binding cleft. As an alternative approach for solving the mutant structure, we performed cryo-EM 
of S532P S1 bound to F-actin. The cryo-EM approach is advantageous, since the structure of 
mutant S1 can be assessed in the presence of F-actin to determine intermolecular interactions 
disrupted by the mutation. 
We formed the complex of S532P S1 bound to F-actin under rigor conditions (in the 
absence of ATP) to determine if the S532P mutation disrupts actomyosin interactions. 
Transmission electron microscopy (TEM) micrographs of negatively stained S1-decorated F-
actin revealed that the position of the lever arm of the mutant more closely resembles the state 
in which myosin-ADP-Pi is weakly bound to actin. In contrast, the lever arm of the control 
structure appears to adopt the rigor conformation. Thus, it is possible that the S532P mutation 
disrupts the transition from weak to strong actin binding. However, the data must be interpreted 
with caution, since the differences observed may result from the effects of the angular 
orientation of the particles. Future approaches will combine cryo-EM and single particle 
analyses to produce 3-dimensional (3D) structural data. For this, we successfully obtained high-
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resolution data of cryo-preserved S532P S1 bound to F-actin. Images of single bound particles 
will be selected to generate 2-dimensional (2D) class averages representing different angular 
orientations of the sample using specialized software. Fourier transforms of 2D class averages 
will be fit with preliminary structural information to generate a model in 3D Fourier space. 
Finally, a mathematical Fourier inversion will be performed by the software to obtain a 3D map 
of the structure. We anticipate that these efforts will produce a high-resolution structure and 
yield a better understanding of the structural basis of myosin-induced DCM. 
Chapter 2, in full, contains unpublished material coauthored by Trujillo, Adriana S.; 
Volkmann, Niels; Hanein, Dorit; Bernstein, Sanford I. The dissertation author was the primary 
investigator and author of this chapter. 
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Chapter 3: Determine whether the myosin DCM mutation S532P 
causes deficits in myosin enzymatic activity and functional output 
of fibers 
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3.1. Introduction 
3.1.1. Drosophila indirect flight muscle system 
We exploited the Drosophila indirect flight muscle (IFM) system to determine the 
mechanistic basis of contractile dysfunction induced by the dilated cardiomyopathy (DCM) 
myosin S532P mutation. Drosophila IFMs constitute the bulk of the thorax and are readily 
accessible via microdissection. Thus, myosin can be purified from isolated IFMs in sufficient 
quantities for biochemical assays, making them an excellent system to determine the molecular 
basis of myosin-induced DCM. Additionally, IFM ultrastructure is highly organized, similarly to 
human skeletal muscles, and our lab has observed severe ultrastructural defects in IFMs of flies 
expressing myosin mutations associated with skeletal muscle myopathies61-63 and 
cardiomyopathy12,13,64 in humans. Furthermore, functional tests are relatively straightforward in 
IFMs compared to other muscles. Flight testing is a simple and low cost strategy to determine 
muscle function.65 Muscle mechanics analyses on isolated skinned fibers can be used to 
determine mechanical properties and cross-bridge rate constants of IFMs in the context of an 
intact myofilament lattice.66  
3.1.2. Biochemical defects associated with the S532P mutation 
Some previous reports suggest that the S532P mutation reduces myosin function and 
muscle functional output. A mouse model expressing the S532P mutation in α-cardiac MHC 
caused a DCM phenotype in which reduced cardiac contractility was associated with decreases 
in actin-activated ATPase activity, reduced ability of myosin to translocate F-actin in vitro, 
reduced myosin step size, and altered kinetics.30 However, in skinned ventricular muscles, 
S532P/+ fibers exhibited a higher rate of force development at saturating Mg-ATP and higher 
Mg-ATP binding rates67, which was not consistent with molecular-level studies using isolated 
myosin.30 Palmer et al. hypothesized that a higher Mg-ATP binding rate may result in a 
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shortened myosin crossbridge lifetime.67 Recent kinetic analyses using recombinant mutant 
human β-cardiac myosin showed that myosin S532P exhibits a reduction in duty ratio (the 
fraction of the ATPase cycle where myosin is bound to actin), due to a reduced occupancy of 
the force holding ADP-bound actomyosin state (A-M-ADP).8 Ujfalusi et al. noted that these 
altered kinetic properties are predicted to reduce contractile function by lowering the load-
bearing capacity of the mutant forms (i.e. more cross-bridges need to be active to sustain load 
relative to wild-type). 
3.1.3. Hypothesis and goals 
  The goal of this aim was to determine the molecular and cell biological defects induced 
by the DCM myosin S532P mutation in the Drosophila model. We exploited the IFM system to 
test the hypothesis that a DCM myosin mutation localized to an actin binding site will weaken 
actin affinity, reduce enzymatic activity of myosin, and cause structural and functional defects in 
muscles.  
3.2. Materials and methods 
3.2.1. Actin co-sedimentation 
  The binding affinity of S1 to F-actin was determined by actin co-sedimentation as 
described previously68,69, with slight modifications. F-actin was polymerized from frozen chicken 
G-actin stocks and stabilized with a 1:1 molar ratio of phalloidin. S1 was purified using the bulk 
His-tagged myosin purification procedure described in Section 2.2.2. Protein purification. 
Subsequently, S1 was centrifuged (Beckman TLA-100.3 rotor, 70,000 RPM, 60 minutes, 4°C) to 
remove insoluble aggregates. The protein concentration in the soluble portion was determined 
by spectrophotometry, and it was diluted to 25 μM. S1 (1.5 μM) was incubated with increasing 
concentrations of phalloidin-stabilized F-actin (0, 0.4, 0.6. 0.8, 1, 1.2, 1.4, 1.6, 1.8, 2, 3, and 4 
μM) in a low salt buffer (100 mM NaCl, 200 mM sodium phosphate, 5 mM MgCl2, 4 mM DTT, 
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pH 7.0) in a total volume of 25 μL. Samples were incubated for 15 minutes on ice and 
centrifuged (Beckman TLA-100.3 rotor, 70,000 RPM, 60 minutes, 4°C). Soluble fractions were 
separated from pellet fractions, and pellets were resuspended in 25 μL of the low salt buffer. 
Samples were applied to a 10% SDS-polyacrylamide gel. Gels were stained with the 
GelCode® Blue Stain Reagent, destained, scanned on an Epson Perfection 1640SU scanner 
using VueScan software (Hamrick), and analyzed using the Un-Scan-It (Silk Scientific) software 
package as reported previously.70 To calculate the bound fraction in actomyosin pellet samples, 
the density of S1 in the pellet fraction relative to total protein content was determined, and the 
fraction of pelleted S1 in S1-only controls was subtracted from this value. Bound fractions were 
plotted over increasing F-actin concentrations, and fit to a hyperbolic function, were Kd was 
defined as the F-actin concentration required to reach half maximal binding (Bmax). 
3.2.2. Generation of mutant (non His-tagged) genomic DNA lines 
We generated transgenic flies expressing the S532P myosin mutation in the germline. 
Transgenic myosin without the His-tag was expressed to avoid potential detrimental effects due 
to disruption of a few N-terminal amino acid residues added during the His-tag cloning 
procedure.19 Transgenic lines were crossed into the Mhc10 background that is null for 
endogenous myosin in indirect fight muscles (IFMs) and jump muscles.45 Myosin was purified 
from microdissected IFMs from homozygous individuals for biochemical assays. Skinned fiber 
mechanics were performed to determine whether this mutation alters IFM fiber force output and 
cross-bridge rate constants (collaboration with Dr. Douglas Swank, Rensselaer PI). We also 
performed functional analyses of IFMs and jump muscles in intact organisms, as well as 
ultrastructural analyses of IFMs to determine whether biochemical changes lead to tissue-level 
defects in our fly model.  
The cloning strategy for the S532P construct is shown in Fig. 3.1.  
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Figure 3.1- Cloning scheme for the Mhc S532P construct, Part I  
The sequential steps of restriction enzyme (RE) digestion and ligation are shown by the blue 
arrows. Each insert generated by RE digestion of the parent vector is shown in red, along with 
RE cut sites. Site-directed mutagenesis (black arrow) was performed to change the serine 
codon to a proline codon at the 531st amino acid coding position of Drosophila Mhc 
(corresponding to position 532 in human MYH7). 
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Subclones containing Mhc exon 10 were generated from a larger plasmid containing a 
19.2 kb Mhc 5’ fragment. Oligonucleotide-directed mutagenesis was performed (QuikChange 
kit, Stratagene) to change the codon in Drosophila Mhc that corresponds to the MYH7 S532P 
nucleotide transition. The following forward (+) and the reverse (-) primers were used for 
mutagenesis: 
S532P (+): 5'-CCCATGGGTATCTTGCCCATCCTGGAGGAAG-3'  
S532P (-): 5'-CTTCCTCCAGGATGGGCAAGATACCCATGGG-3'  
The mutated exon was sequenced for confirmation and subclones containing the mutant 
fragment were inserted into larger cloning intermediates to produce the mutant 5’ Mhc fragment. 
For the final cloning step, a 19.2 kb 5’ Mhc fragment carrying the S532P mutation was removed 
from its vector by EagI digestion, and ligated to a 3’ Mhc fragment in a pCaSpeR P element 
vector containing the miniwhite (w+) selectable eye color marker (Fig. 3.2). The final plasmid 
was purified using the QIAfilter Plasmid Maxi Kit (Qiagen Inc.) and the entire Mhc coding region 
was sequenced for verification by Eton Bioscience.  
Embryonic injection was performed by Bestgene, Inc. to incorporate the transgenic insert 
randomly into the germline via P element transformation.44 A total of 39 transgenic lines were 
obtained. Several lines mapping to the 3rd chromosome were crossed into the Mhc10 myosin 
null background. Lines that mapped to the second chromosome were not used since it contains 
the endogenous Mhc gene.  
Polyacrylamide gel electrophoresis was performed to determine MHC protein levels in 
these lines, by comparing the ratio of myosin to actin between transgenic flies and yw (wild-
type) controls, as described previously.46 Each lysate consisted of six upper thoraces of 0-2 
day-old flies. Only lines with wild-type MHC protein levels were chosen for further experiments.  
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Figure 3.2- Cloning scheme for the Mhc S532P construct, Part II 
A 19.2 kb 5’ Mhc fragment carrying the S532P mutation was removed from its vector by EagI 
digestion, and ligated to a Mhc 3’ fragment in a pCaSpeR P element vector.  
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RT-PCR confirmed expression of RNA encoding the mutant protein and the absence of 
endogenous myosin expression in IFMs. Additionally, cDNA was amplified using Mhc specific 
primers to confirm the absence of alternative splicing defects in these lines. RNA isolation, 
cDNA synthesis, and PCR amplification were performed as described in Section 2.2.1. for the 
His-tagged line, using the following primer pairs: 
Exons 2-8:  
(+) 5’-TGGATCCCCGACGAGAAGGA-3’ 
(-) 5’-GTTCGTCACCCAGGGCCGTA-3’ 
Exons 8-10: 
(+) 5’-CGATACCGCCGAGCTGTACAG-3’ 
(-) 5’-CAGCTGGTGCATGACCAAGTGGGC-3’ 
Exons 8-12:  
(+) 5’-TCTGGATACCCAGCAGAAGCGT-3’ 
(-) 5’-GAGCTTCTTGAAGCCCTTACGG-3’  
Exon 15:  
(+) 5’-CTCAAGCTCACCCAGGAGGCT-3’ 
(-) 5’-GGGTGACAGACGCTGCTTGGT-3’ 
For simplicity, lines S532P-9, S532P-23, and S532P-34 were respectively renamed as 
S532P-L1, S532P-L2. and S532P-L3. 
3.2.3. Myosin purification and ATPase assay 
Myosin purification: Myosin was purified from IFMs as described previously43 with minor 
modifications. Dorsal longitudinal IFMs were dissected from 80-120 transgenic flies in 1 mL 
York Modified Glycerol [YMG: 20 mM potassium phosphate buffer pH 7.0, 1 mM EGTA, 2 mM 
MgCl2, 50% glycerol, 20 mM DTT, and Roche complete mini protease inhibitor (1 tablet per 10 
mL solution)] on ice. The sample was centrifuged at 15,000 x g, 5 minutes, 4°C, and the pellet 
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was resuspended in YMG containing 2% Triton-X. The sample was incubated for 30 minutes on 
ice to permeabilize cell membranes, then centrifuged at 15,000 x g, 5 minutes, 4°C. Triton-X 
was removed by resuspending the pellet in 1 mL YM buffer (same as YMG but without glycerol). 
The sample was centrifuged at 15,000 x g, 5 minutes, 4°C. The pellet was resuspended in 82.5 
μL of myosin extraction buffer (1.0 M KCl, 50 mM potassium phosphate buffer pH 6.8, 10 mM 
sodium pyrophosphate, 5 mM MgCl2, 0.5 mM EGTA, and 20 mM DTT) for 15 minutes and 
centrifuged at 15,000 x g, 5 minutes, 4°C. The supernatant was removed, and the pellet 
discarded. Extracted myosin in the soluble portion was precipitated by decreasing [KCl] to 40 
mM and incubating for 16 hours at 4°C. The sample was centrifuged (Beckman TLA-100.3, 
100,000 x g, 20 minutes, 4°C) and the pellet was dissolved in 13.5 μL buffer (2.4 M KCl, 100 
mM histidine, 0.5 mM EGTA, 20 mM DTT, pH 6.8). The [KCl] was slowly diluted to 300 mM to 
precipitate actomyosin, and the sample was centrifuged (Beckman TLA-100.3, 60,000 x g, 25 
minutes, 4°C). The supernatant was separated, and [KCl] was diluted to 30 mM to precipitate 
myosin. Following centrifugation (Beckman TLA-100.3, 60,000 x g, 25 minutes, 4°C), the pellet 
was resuspended in 33 μL myosin storage buffer (0.5 M KCl, 20 mM MOPS, pH 7.0, 2 mM 
MgCl2, and 20 mM DTT) and the purified myosin was diluted to a concentration of 2 mg/mL. 
ATPase assay: ATPase activity of full-length myosin was measured using [γ-32P]-ATP as 
described previously.43 For Ca-ATPase activity, a total of 2 µg of myosin was incubated in 10 
mM imidazole, pH 6.0, 100 mM KCl, 10 mM CaCl2, and 1 mM [γ-32P]-ATP at room temperature 
for 15 minutes. To determine Mg2+ basal and actin-stimulated Mg-ATPase activities, 2 µg of 
myosin was incubated in 10 mM imidazole, pH 6.0, 20 mM KCl, 0.1 mM CaCl2, 1 mM MgCl2, 1 
mM [γ-32P]-ATP in the absence or presence of increasing concentrations of F-actin (0.1-2 µM). 
Following centrifugation, the organic phase containing [γ-32P]-ATP was extracted by adding 
aliquots of the soluble portion to 0.5 ml of 5% ammonium molybdate, 2 ml of 1.25 N HClO4, and 
2.5 ml of isobutanol-benzene (1:1). A total of 1 mL of the organic phase containing [γ-32P]-ATP 
was assayed for radioactivity with a scintillation counter. Mg2+ basal ATPase activities were 
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subtracted from actin-activated ATPase values, which were fit with the Michaelis Menten 
equation to determine actin-stimulated ATPase activity (Vmax) and actin affinity relative to 
ATPase (Km).  
3.2.4. Muscle mechanics 
Detailed procedures for mechanics experiments are described in Swank et al. 66 
IFM fiber preparation: Dorsal longitudinal IFM fibers were dissected from 3 day-old 
females in skinning solution (pCa 8.0, 5 mM MgATP, 1 mM free Mg2+, 0.25 mM phosphate, 5 
mM EGTA, 20 mM N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid [BES, pH 7.0], 175 mM 
ionic strength [adjusted with Na methane sulfonate], 1 mM DTT, 50% glycerol and 0.5% Triton 
X-100). Fiber bundles were demembranated for 1 hour at 6°C, then transferred to storage 
solution (same as skinning solution but without Triton X-100). Individual fibers were separated 
from the IFM bundle and split in half longitudinally with tungsten wire probes. Both ends of the 
fiber were fastened with aluminum foil t-clips. The fiber was transferred to a mechanics rig and 
submerged in relaxing solution (pCa 8.0, 12 mM MgATP, 30 mM creatine phosphate, 600 U/mL 
creatine phosphokinase, 1 mM free Mg2+, 5 mM EGTA, 20 mM BES at pH 7.0, 1 mM DTT; 200 
mM ionic strength 200 mM [adjusted with sodium methanesulfonate]), where it was hooked onto 
a force transducer and servo motor.  
All measurements were obtained at a temperature of 15°C. The fiber was stretched until 
slack was removed. The fiber length between the t-clips was measured, and the fiber was 
stretched by 5% of its initial length. The width and height of the fiber were subsequently 
measured, and the cross-sectional area was calculated assuming an ellipsoid shape. Passive 
tension (Po) was recorded in relaxing solution (pCa 8.0), and a small amplitude, sinusoidal 
length perturbation was applied at various frequencies of oscillations to measure passive 
stiffness (see details below). The fiber was activated by partially exchanging the bathing solution 
with activating buffer (same as relaxing solution, with pCa adjusted to 4.0) to bring the pCa to 
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5.0. The fiber was stretched in 2% increments (relative to the fiber length between the t-clips) 
until maximum power was obtained (Fig. 3- eq 5), in order to determine the optimal sarcomere 
length. Following the power optimization, active tension was recorded (Ao) to derive net tension 
(Fo =Ao-Po) and sinusoidal analysis was performed at decreasing ATP concentrations.   
Sinusoidal analysis and mechanical rate constants: Sinusoidal analysis was performed 
to determine muscle stiffness and mechanical rate constants of the fibers. The muscle was 
oscillated with a small amplitude sine wave (0.125% muscle length, peak to peak) at 
frequencies ranging from 0.5 to 650 Hz. For each frequency, the amplitude and phase 
differences associated with the sinusoidal tension response were calculated to determine the 
complex modulus (Fig. 3.3- eq 1 to eq 3). The complex modulus can be further separated into 
the viscous and elastic moduli. The viscous modulus is the out-of-phase component in the 
Nyquist plot, and is related to the work and power produced by the fiber (Fig. 3.3- eq 4-5). The 
elastic modulus represents an in-phase component of the complex modulus and is influenced 
by the spring-like properties of the molecular machinery. The complex modulus was fit to a 3-
term equation (Fig. 3.3- eq 6) to determine exponential rate processes (A, B, and C). This 
equation was originally determined by Kawai and Brant71 and has been modified by Swank et 
al.72 to better fit the IFM system. Process A is influenced by the viscoelastic properties of the 
fiber structure, and is not dependent on enzymatic steps of the cross-bridge cycle.73 Process B 
reflects a work producing step related to actin binding. Process C reflects a work absorbing step 
prior to and during detachment from actin. In the Nyquist plot, Processes B and C appear as 
lower and upper hemispheres, respectively, with associated frequencies b and c. Frequencies b 
and c were multiplied by 2π to convert from frequency to time (s−1), to determine rate constants 
associated with work producing (2πb) and work absorbing (2πc) steps of the cross-bridge cycle. 
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Figure 3.3- Equations used for muscle mechanics experiments via sinusoidal analysis 
Equations (eq 1-eq 6) were developed by Kawai et al.71 Eq 6 was modified by Swank et al. to 
better fit the IFM system.72 
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ATP response experiments: To elucidate cross-bridge kinetics related to ATP-induced 
dissociation of myosin from actin, the concentration of ATP in the fiber bathing solution was 
varied from 20 mM to 0.5 mM while performing sinusoidal analysis. Values for fmax were plotted 
over changing [ATP], and fit with the Michaelis Menten equation to determine actin-stimulated 
ATPase activity (Vmax) and actin affinity relative to ATPase (Km). 
3.2.5. Flight and jump tests 
Transgenic mutant and control females were reared at 25°C, acclimated to room 
temperature for 1 hour, and tested at room temperature.  For flight testing, a Plexiglas box (43 
cm x 27.5 cm x 43 cm) with a light source at the top was used as a test chamber.65  At least 100 
flies from each genetic line/age were tested.  Each fly was scored for its ability to fly in an 
upward (U=6), horizontal (H=4), or downward (D=2) fashion towards a light source, and flies 
with no flight ability received a score of zero (N=0).  To calculate the flight index, an equation 
representative of average flight ability was used: Flight Index (FI)= 6*U/T+4*H/T+2*D/T+0*N/T, 
where U, H, D, and N represent each fly trajectory listed above, and T=total # of flies.  For jump 
tests, the wings were clipped, and each fly was placed on an inverted fly food vial with 
concentric rings drawn 0.5 cm apart to measure jump distance. Each fly was tactilely stimulated 
to jump, and the jump distance was recorded for 10 trials per fly. The top 3 of 10 jump distances 
were reported, and a total of N=40 flies were tested per line/age. 
3.2.6. Transmission electron microscopy of skeletal muscles 
 Hemi-thoraces were dissected and treated with a relaxing solution containing 10 mM 
EGTA prior to fixation. The following steps were performed on ice: After incubation in 2 mL 
primary fixative (3% formaldehyde, 3% glutaraldehyde in 0.1 M sodium cacodylate, pH 7.4), 
samples were washed 6 X in 2 mL wash buffer (0.1 M sodium cacodylate, pH 7.4). Samples 
were incubated in 2 mL secondary fixative (1% OsO4, 0.1 M sodium cacodylate buffer, and 10 
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mM MgCl2, pH 7.4) for 2 hours, then washed 3 X in HPLC-H2O. All subsequent steps were 
performed at room temperature. An acetone dehydration series was performed at 30 minutes 
each: 25%, 50%, 75%, 95%, and 3X 100% anhydrous acetone. Samples were infiltrated in fresh 
Epon mix [16.2 mL EM bed-812, 10.0 mL Dodecenyl Succinic Anhydride, 8.9 mL NMA (Nadic 
Methyl Anhydride), 0.6 mL 2,4,6-Tris(dimethylaminomethyl)phenol (DMP-30)] for 2 hours each 
using increasing ratios of Epon:dry acetone (1:3, 1:1, 3:1). Following infiltration in 100% Epon 
for 16 hours, samples were oriented in Epon filled BEEM capsules, and polymerized at 60°C for 
1 day under vacuum.  Thin sections (50 nm) were cut using a Diatome diamond knife on a Leica 
Ultramicrotome, and collected on formvar-coated grids.  Grids were stained with 2% uranyl 
acetate for 20 minutes. Images were obtained at 120kV on a FEI Tecnai 12 transmission 
electron microscope. 
Measurements of average distances between adjacent thick filaments were performed 
with a custom-written Python script. A representative image of the original micrograph 
(220,000x magnification) is shown in Fig. 3.4A. For this procedure, the image was inverted 
using the cv2.threshold function, and grain noise was minimized using the 
cv2.adaptiveThreshold, cv2.morphologyEx, and cv2.blur functions. Thick filament centers were 
detected using the cv2.HoughCircles function and the following parameters: 
HOUGH_GRADIENT, 1, 100, param1=100, param2=18, minRadius=9, maxRadius =15. 
Detections were overlayed onto the original micrograph to confirm that detections align with 
thick filament centers (Fig. 3.4B). The positions of thick filament centers that were missing from 
detections were manually added, and erroneous detections were removed. The pixel 
coordinates of the six closest lattice neighbors from each thick filament center were determined 
automatically using the Nearest Neighbor Search algorithm. The maximum pixel distance 
between neighbor detections was set to a value that excludes non-neighbors; A topographical 
map of neighbor assignments was generated for confirmation (Fig. 3.4C). Average neighbor 
pixel distances were determined for thick filament centers containing six true lattice neighbors, 
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which excluded measurements for thick filament centers located on the edges of micrographs. 
For each biological sample, average pixel distances between adjacent thick filaments were 
determined for ≥ 700 thick filament centers. Values were converted to nanometers using the 
scale bar, and thick filament distances were averaged for each biological replicate. 
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Figure 3.4- Analysis of inter-thick filament spacing of IFMs 
A) Transmission electron microscopy image of IFMs in transverse orientation from 3 week-old 
transgenic wild-type PwMhc2 controls.  B) Thick filament centers were detected in a semi-
automated fashion, and overlayed onto the original micrograph to confirm accuracy of 
detections. C) The x,y coordinates of centers were determined using a specialized Python-
based software. Scale bars, 0.1 μm. 
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3.3. Results 
 
3.3.1. Actin co-sedimentation 
Co-sedimentation assays were performed to estimate the binding affinity of S532P S1 
for F-actin. Binding curves were generated by incubating increasing amounts of F-actin with 
fixed amounts of control or mutant myosin S1 isolated from His-tagged lines (Chapter 2). 
Following centrifugation, a majority of S1 remained soluble in actin-free S1 controls, while F-
actin was insoluble in S1-free actin controls (Fig. 3.5A). Electrophoretic gels of centrifuged 
samples were scanned and densities of S1 bound fractions were fit to a hyperbolic function to 
determine binding affinity (Kd) for F-actin (Fig. 3.5B).  Both recombinant mutant and control S1 
exhibited tight binding affinity for F-actin (Kd= 2003 ± 1040 nM for S532P; 1260 ± 963 nM for 
control), and Kd values did not significantly differ (P= 0.42). However, the average Kd value for 
the S532P mutant S1 was ~1.6 fold higher relative to control S1, indicating a trend towards 
lower actin affinity in this mutant. Though the co-sedimentation method is a standard approach 
for measuring actin binding affinity, it is challenging to obtain accurate Kd measurements using 
this method due to the irreversible binding of actomyosin during sedimentation. Thus, we also 
utilized other methods to determine whether the S532P mutation affects actin binding, including 
structural-based approaches (Chapter 2), biochemical analysis of actin-stimulated ATPase 
activity (Chapter 3), and muscle mechanics (Chapter 3).  
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Figure 3.5- Co-sedimentation of S532P IFI S1 and control IFI S1 for F-actin 
A) A representative SDS-polyacrylamide gel showing insoluble pellet (P) fractions of F-actin and 
IFI S1-containing samples over increasing F-actin concentrations (Lanes 5-15: 0.4, 0.6. 0.8, 1, 
1.2, 1.4, 1.6, 1.8, 2, 3, and 4 μM). Supernatant (S) and pellet (P) fractions of samples containing 
S1 or F-actin alone are shown as controls (Lanes 1-4). B) The bound fractions in actomyosin-
containing samples were determined via densitometry and plotted vs. F-actin concentration. To 
determine bound fractions, the density of S1 in the pellet fraction relative to total protein content 
was calculated, and the fraction of pelleted S1 in a S1-only control was subtracted from this 
value. Data are reported as mean ± SD. To determine actin binding affinity, the dissociation 
constant of S1 for F-actin (Kd ) was defined as the F-actin concentration required to reach half 
maximal binding (Bmax). 
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3.3.2. Fly line validation 
To study the disease mechanisms induced by a myosin-induced DCM mutation, we 
used P element transformation to engineer fly lines harboring the S532P myosin mutation 
lacking a His-tag. Since lines produced by P element transformation can exhibit position effects 
due to the chromosomal site of insertion, we produced multiple transgenic lines to ensure 
reproducibility of in vivo functional analyses. A total of 39 transgenic lines were obtained. Lines 
mapping to the third chromosome were crossed into the Mhc10 genetic background that is null 
for endogenous myosin in IFMs and jump muscles.45  
Table 3.1- Validation S532P fly lines 
Protein expression levels in IFMs from S532P lines (L1, L2, and L3) relative to wild-type yw flies 
were determined using densitometry. Data are reported as mean ± SEM. RT-PCR of RNA 
isolated from IFMs was performed to verify that each line expresses mutant myosin in absence 
of endogenous myosin, and to verify that alternative exon splicing was not disrupted. ✓ 
represents verification of the mutation or normal IFI alternative exon. 
 
We selected the fly lines with wild-type protein expression levels for further analyses. 
SDS-PAGE analysis of upper thoraces of young mutant flies confirmed that these lines express 
normalized ratios of myosin to actin at wild-type levels (Table 3.1). RT-PCR of IFM lysates 
confirmed expression of RNA encoding mutant myosin, the absence of endogenous myosin 
expression, and the absence of alternative splicing defects in these lines (Table 3.1).  
  
Genotype Protein 
expression 
Mutation 
present 
Exon 
3b 
Exon 
7d 
Exon 
9a 
Exon 
11e 
Exon 
15a 
S532P-L1 100.6 ± 3.8 ✓ ✓ ✓ ✓ ✓ ✓ 
S532P-L2 101.5 ± 1.3 ✓ ✓ ✓ ✓ ✓ ✓ 
S532P-L3 99.0 ± 2.2 ✓ ✓ ✓ ✓ ✓ ✓ 
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3.3.3. ATPase assay 
Steady-state ATPase parameters of myosin obtained from dissected IFMs were 
assessed to determine the impact of the S532P mutation on the enzymatic activity of myosin 
(Fig. 3.6). Both basal Mg-ATPase and Ca-ATPase did not significantly differ for S532P myosin 
compared to wild-type myosin (0.22 ± 0.08 sec-1 vs. 0.28 ± 0.11 sec-1, P=0.32 for Mg-ATPase; 
10.81 ± 6.38 sec-1 vs. 15.77 ± 3.33 sec-1, P=0.16 for Ca-ATPase).  Mg-ATPase activity in the 
presence of increasing concentrations of F-actin was measured to determine if the S532P 
mutation affects actin-dependent activity. The Vmax (maximum ATPase rate) of actin-stimulation 
was reduced ~2-fold for S532P relative to wild-type myosin (0.59 ± 0.28 sec-1 vs. 1.86 ± 0.49 
sec-1, P=0.0011). The Km of actin concentration required to reach 50% Vmax did not differ relative 
to wild type (0.68 ± 0.33 uM vs. 0.80 ± 0.39 uM, P= 0.61).  
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Figure 3.6- ATPase activity of S532P myosin 
Full-length myosin isolated from IFMs of S532P lines and wild-type transgenic controls 
(PwMhc2) was assessed for the following ATPase activity parameters: A) Basal Mg-ATPase 
activity, B) Ca-ATPase activity, C) Vmax of actin-activated Mg-ATPase, and D) actin affinity 
relative to ATPase (Km). E) To determine actin-activated activity, Mg2+ basal ATPase activities 
were subtracted from measured basal ATPase values and over increasing concentrations of F-
actin. Values were fit with the Michaelis-Menten equation to determine the Vmax and Km. Data 
are reported as mean ± SD. Statistical significance was determined using Student’s t-tests (ns= 
not significant, ***p<0.001).  
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3.3.4. Muscle mechanics 
A sinusoidal analysis was performed to determine muscle mechanical properties 
influenced by the S532P mutation. For this, individual fibers were isolated from IFMs of 2-3 day-
old flies and subjected to small length changes in a mechanical rig. The amplitudes and phases 
of force and length traces were measured to elucidate mechanical properties such as power, 
force, and rate constants of the myosin cross-bridge cycle. Fibers isolated from multiple mutant 
fly lines (L1, L2, and L3) were independently assessed. The rate constant 2πb, which is 
influenced by the rates of attachment to actin and/or the powerstroke step, was significantly 
lower for fibers from all three mutant lines compared to controls (Table 3.2, p<0.05, One-Way 
ANOVA Dunn’s Method). The rate constant 2πc, which is influenced by the rate of detachment 
from actin, was significantly higher for fibers from all three mutant lines compared to controls 
(Table 3.2, p<0.001, One-Way ANOVA Holm-Sidak method). 
Table 3.2- Muscle apparent rate constants of S532P fibers 
A sinusoidal analysis was performed on PwMhc2 (N = 10), S532P-L1 (N = 8), S532P-L2 (N = 
6), and S532P-L3 (N = 8) IFM fibers isolated from homozygotes. Full genotypes are shown in 
parenthesis: S532P lines (Mhc10/Mhc10; P[S532P]/P[S532P]); PwMhc2 transgenic controls 
(P[PwMhc2]/P[PwMhc2]; Mhc10/Mhc10). Mean ± SEM are reported. One-way ANOVAs were 
performed to determine statistical significance (***p<0.001, Holm-Sidak method; *p<0.05, 
Dunn’s Method).  
Genotype A B 2πb (s-1) C 2πc (s-1) 
PwMhc2 341.8 ± 
33.4 
2250.3 ± 
237.1 
1680.8 ± 74.4 2190 ± 
218.9 
2845.0 ± 
122.6 
S532P-L1 356.9 ± 
70.6 
624.3 ± 
131.6* 
945.6 ± 39.6* 550.4 ± 
107.7* 
6046 ± 
506.0*** 
S532P-L2 309.8 ± 
9.24 
485.2 ± 
40.9* 
766.6 ± 25.7* 436.3 ± 
25.3* 
6660.2 ± 
650.32*** 
S532P-L3 292.6 ± 
19.3 
575.9 ± 
97.3* 
878.9 ± 42.3* 552.4 ± 
83.0* 
6321.7 ± 
582*** 
 
Fibers from all three mutant lines displayed depressed maximum power production 
(p<0.05, One-Way ANOVA Dunn’s Method) (Fig. 3.7) and lower frequency of maximal power, 
fmax (p<0.001, One-Way ANOVA Holm-Sidak method) (Fig. 3.7). To determine actin-stimulated 
ATPase activity (Vmax) and actin affinity relative to ATPase (Km), we varied ATP concentration 
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from 20 mM to 0.5 mM while performing a sinusoidal analysis. Values for fmax were plotted over 
changing [ATP], and fit with the Michaelis-Menten equation (Fig. 3.8). Vmax was significantly 
lower for S532P mutant fibers (p<0.001, One-Way ANOVA Holm-Sidak method), but there was 
no change in Km. Overall, the transgenic myosin form produced by our models shows disrupted 
actomyosin interactions, causing reductions in actin-stimulated ATPase activity and power 
output. 
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Figure 3.7- Skinned fiber power output of S532P fibers 
Maximum power output and the frequency at which maximum power is generated (fmax) were 
measured by sinusoidal analysis of IFM fibers from homozygotes. Full genotypes are shown in 
parenthesis: S532P lines (Mhc10/Mhc10; P[S532P]/P[S532P]); PwMhc2 transgenic controls 
(P[PwMhc2]/P[PwMhc2]; Mhc10/Mhc10). One-Way ANOVAs were employed to determine 
statistical significance, where *p<0.05, Dunn’s method; ***p<0.001, Holm-Sidak method. fmax 
values are indicated by the vertical dashed lines. N=10 for PwMhc2, N=8 for S532P-L1, N=6 for 
S532P-L2, and N=8 for S532P-L3. 
Genotype Max Power 
(W/m3) 
fmax (Hz) 
PwMhc2 164 ± 15 191 ± 5 
S532P-L1 86 ± 20* 148 ± 4*** 
S532P-L2 63 ± 6* 131 ± 4*** 
S532P-L3 71 ± 16* 143 ± 4*** 
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Figure 3.8- ATP response of S532P fibers 
Sinusoidal analysis was performed with varied [ATP] to determine actin-stimulated ATPase 
activity (Vmax) and actin affinity relative to ATPase (Km), Values for fmax were plotted over 
changing [ATP], and fit with the Michaelis-Menten equation. Full genotypes of homozygotes are 
shown in parenthesis: S532P lines (Mhc10/Mhc10; P[S532P]/P[S532P]); PwMhc2 transgenic 
controls (P[PwMhc2]/P[PwMhc2]; Mhc10/Mhc10). Statistical significance for Vmax is represented 
by ***p<0.001, One-Way ANOVA Holm-Sidak method. Horizontal bars indicate statistical 
differences in fmax values (*, p<0.05, One-Way ANOVA Dunn’s Method). N=10 for PwMhc2, N=8 
for S532P-L1, N=6 for S532P-L2, and N=8 for S532P-L3. 
  
Genotype Vmax Km 
PwMhc2 243.9 ± 7.5 3.0 ± 0.6 
S532P-L1 173.6 ± 3.1*** 1.7 ± 0.2 
S532P-L2 162 ± 5.4*** 2.2 ± 0.5 
S532P-L3 172.5 ± 10.2*** 1.8 ± 0.1 
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3.3.5. Flight and jump tests 
Mutant lines were tested for flight and jump muscle function compared to PwMhc2 (P 
element-transformed wild-type) controls to determine if the S532P mutation causes tissue level 
muscle functional defects. At 2 days of age, homozygous S532P lines L1 and L3 showed no 
significant difference in flight ability relative to controls (Fig. 3.9A). Homozygous line S532P-L2 
showed reduced flight ability at this age compared to controls [arbitrary units (A.U.) ± S.E.M: 
2.70 ± 0.16 vs. 3.70 ± 0.15]. All three lines (L1-L3) displayed reduced flight ability compared to 
controls by ages 1-week (1.94 ± 0.16, 1.75 ± 0.16, and 2.48 ± 0.12 vs. 3.52 ± 0.12 A.U.) and 3-
weeks (1.42 ± 0.17, 1.76 ± 0.14, and 1.84 ± 0.12 vs. 3.32 ± 0.13 A.U.). Changes in flight ability 
within each line were compared between young 2 day-old flies and aged 3 week-old flies to 
determine if functional impairments are progressive, akin to the age-related disease progression 
observed in DCM patients. All three S532P lines exhibited a greater decline in flight ability from 
2 days to 3 weeks of age compared to controls. Two-way ANOVAs determined that the effects 
of genotype (p<0.0001) and age (p<0.0001) as two independent factors, as well as the 
interaction between age and genotype (p<0.0001), contribute to statistically significant 
differences between groups. Overall, the S532P mutation causes defects in flight ability that are 
progressive with age. We also assessed heterozygotes to determine if the S532P mutation 
causes dominant defects in muscle function, akin to the human condition. Heterozygotes display 
no defects in flight ability compared to controls at 3 weeks of age (Fig. 3.9B), the same age that 
homozygotes display severe functional defects, suggesting that the detrimental effects of the 
mutation on muscle function are not dominant. 
Mean jump distance was also reduced in all three homozygous mutant lines (L1, L2, and 
L3) compared to controls at ages 2-day (6.17 ± 0.16, 6.58 ± 0.15, and 4.86 ± 0.13 cm vs. 7.08 ± 
0.16 cm) and 1-week (6.41 ± 0.14, 5.76 ± 0.17, and 5.32 ± 0.12 cm vs. 7.89 ± 0.14 cm) (Fig. 
3.10). Two-way ANOVAs demonstrated significant differences between control and mutant lines 
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(p<0.0001), while the effects of age as an independent factor were not statistically significant. 
Though there was a statistically significant interaction between age and genotype (p<0.0001), 
this could be explained by the increase in jump muscle function observed in controls with age, 
rather than a deterioration in muscle function with age in mutant lines. Jump muscle function did 
not worsen from 2-days to 1-week of age in two of the lines tested (L1 and L3), contrary to the 
progressive and rapid decline in muscle function observed in IFMs. 
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Figure 3.9- Flight abilities of S532P mutant lines 
Homozygous (A) and heterozygous (B) S532P mutant lines (L1, L2, and L3) were crossed into 
a Mhc10 (myosin-null in IFMs and jump muscles) background. Flight index was calculated as 
6*U/(# flies) +4*H/(# flies) +2*D/(# flies) +0*N/(# flies) where each fly was assigned a score for 
flight upward (U), horizontally (H), downward (D) or the inability to fly (N). Values represent 
mean ± SEM. A total of N≥100 flies were tested for each line/age. A) Full genotypes of 
homozygotes are shown in parenthesis: S532P lines (Mhc10/Mhc10; P[S532P]/P[S532P]); 
PwMhc2 transgenic controls (P[PwMhc2]/P[PwMhc2]; Mhc10/Mhc10). A two-way ANOVA was 
employed to test if the effects of genotype and age were significant (****p<0.0001, ns= non-
significant). Multiple comparisons between mutant lines and age-matched controls are also 
shown. B) Full genotypes of heterozygotes are shown in parenthesis, where “-“ indicates there 
is no P element on the homologous chromosome: S532P/+ lines (Mhc10/+; P[S532P]/-); 
PwMhc2/+ transgenic controls (P[PwMhc2]/-; Mhc10/+). A one-way ANOVA was employed to 
determine statistical significance between mutant lines and controls (ns= non-significant). 
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Figure 3.10- Jump abilities of S532P mutant lines 
Homozygous S532P mutant lines (L1, L2, and L3) were crossed into a Mhc10 (myosin-null in 
IFMs and jump muscles) background. The top 3 of 10 jump distances were reported, and a total 
of N=40 flies were tested per line/age. Values represent mean ± SEM. Full genotypes are 
shown in parenthesis: S532P lines (Mhc10/Mhc10; P[S532P]/P[S532P]); PwMhc2 transgenic 
controls (P[PwMhc2]/P[PwMhc2]; Mhc10/Mhc10). A two-way ANOVA was employed to test if the 
effects of genotype and age were significant (ns- non-significant, ****p<0.0001). Multiple 
comparisons between mutant lines and age-matched controls are also shown (*p<0.05 and 
****p<0.0001). 
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3.3.6. Transmission electron microscopy of IFMs 
Transmission electron microscopy was performed on IFMs from aged 3 week-old S532P 
homozygous mutants and controls to determine if expression of the S532P mutation causes 
defects in myofibrillar assembly or maintenance. Transverse sections of mutants and controls 
displayed myofibrils with normal, rounded morphology (Fig. 3.11: A-B), and a normal double 
hexagonal array of thick and thin filaments (Fig. 3.11: C-D). In longitudinal sections, myofibrils 
displayed normal parallel organization (Fig. 3.12: A-B), and sarcomeres displayed normal 
organization with intact myofilaments (Fig. 3.12: C-D). No differences in average inter-thick 
filament spacing distances (Fig. 3.11E) or sarcomere lengths (Fig. 3.12E) were detected 
between mutants and controls. Overall, no disruption in sarcomere ultrastructure was observed 
in S532P mutants, suggesting that flight impairment in these lines was not caused by 
myofibrillar assembly defects or degeneration. 
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Figure 3.11- Ultrastructure of S532P IFMs in transverse orientation 
Transmission electron micrographs of thin-sectioned IFMs in transverse orientation were 
obtained from 3 week-old homozygous PwMhc2 control or S532P mutant lines (L1 or L2) in a 
Mhc10 (myosin-null in IFMs and jump muscles) background. A-B) Low magnification images 
showing myofibrillar morphology. MF- myofibril, M- mitochondrion. Scale bar, 0.5 µm. C-D) 
High magnification images showing hexagonal array of thick and thin filaments Scale bar, 0.1 
µm. E) Inter-thick filament spacing averages were determined from micrographs using a 
custom-written Python script. Values represent mean ± SD. Statistical significance was 
determined using Student’s t-tests (ns= not significant). 
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Figure 3.12- Ultrastructure of S532P IFMs in longitudinal orientation 
Transmission electron micrographs of thin-sectioned indirect flight muscles (IFMs) in 
longitudinal orientation were obtained from 3 week-old homozygous PwMhc2 control or S532P 
mutant flies in a Mhc10 (myosin-null in IFMs and jump muscles) background. A-B) Low 
magnification images showing myofibrillar organization. MF- myofibril, M- mitochondrion. Scale 
bar, 2 μm. C-D) High magnification images showing sarcomeres bordered by Z-disks 
(arrowheads). Scale bar, 0.5 μm. E) Average sarcomere lengths were measured using Image-J 
software. Values represent mean ± standard deviation. Statistical significance was determined 
using Student’s t-tests, where NS= non-significant difference compared to controls. 
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3.4 Discussion 
The S532P myosin DCM mutation, located within the actin-binding region of the motor 
domain, was introduced into Drosophila myosin heavy chain to determine the biochemical, cell 
biological, and physiological mechanisms of disease. Given that the S532 residue localizes to 
an α-helix within an actin binding site74, we hypothesized that a proline substitution at that 
residue would bend or kink the helix and disrupt actin binding affinity. 
Though we observed a trend of lower affinity (i.e. higher Kd) in the mutant compared to 
wild-type myosin using the co-sedimentation approach, the difference was not significant. 
However, it is challenging to determine an accurate dissociation constant using this method, 
since detachment of actin is limited in insoluble actomyosin fractions. Thus, we performed a 
sinusoidal analysis on skinned IFM fibers to determine rate constants associated with actin 
binding. The muscle apparent rate constant 2πb was lower in S532P homozygous fibers, 
suggesting that the mutation slows a work-generating step involved in actin attachment and/or 
the powerstroke step. The rate constant 2πc was higher in mutant fibers, suggesting that the 
mutation lowers the duration of one or more strong actin binding states (i.e. with ADP bound 
state after Pi release, or the nucleotide-free state), causing myosin to detach more quickly from 
actin. Overall, S532P myosin spends less time bound to actin during the cross-bridge cycle, 
which is expected to lower the duty ratio (fraction of myosin heads bound to actin) and decrease 
force output.75 It remains unknown whether the mutation affects the cooperativity of myosin 
binding events. The precise actin binding step(s) of the chemomechanical cycle affected by the 
mutation are also unclear. Given the effects on both 2πb and 2πc, it is possible that the 
mutation disrupts the transition from the weakly-bound to strongly-bound actomyosin states. 
Future studies will determine the exact intramolecular structural rearrangements associated with 
alterations in actin binding properties using cryo-electron microscopy (see Chapter 2). 
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Previous reports that modeled the S532P mutation in mouse α-MyHC support our 
hypothesis that this mutation interrupts actomyosin interactions. Schmitt et al. determined the 
actin binding properties of S532P myosin at the single molecule level using a laser trap assay.30 
The magnitude of displacement associated with the step size was significantly depressed in the 
mutant. Surprisingly, the duration of the time in which myosin remained bound to actin after the 
powerstroke (ton) was longer. However, the authors acknowledged that individual kinetic steps 
affected by ton could not be determined at the sub-saturating levels of ATP used in the assay, 
since ton is limited by both the rates of MgATP binding and ADP release. Muscle mechanics 
revealed that the rate constant 2πb is higher in skinned S532P/+ mouse myocardial fibers67, 
contrary to the depressed motor function observed in molecular level studies on myosin isolated 
from homozygous mutants hearts.30 Palmer et al. attributed this discrepancy to potential effects 
of sample preparation, assay design, or differences between genotypes or post-translational 
modifications.67 They also acknowledged that some of the data were slightly misrepresented by 
the model equation for complex modulus, which may also account for the inconsistency. Our 
data suggest that the rate constant 2πb is lower in S532P Drosophila IFMs. Differences in the 
backbone between mouse α-MyHC and Drosophila IFI MHC may have a disparate effect on 
their actin binding properties. Additionally, the exact ratio of mutant to non-mutant α-MyHC in 
mouse S532P/+ fibers is unknown.67 Effects of genotype may account for some discrepancies, 
since there may be functional compensation by wild-type myosin in mouse S532P/+ fibers. Rate 
constant 2πc was significantly higher in mouse S532P/+ fibers at intermediate concentrations 
[0.4-0.8 mM] of Mg-ATP, consistent with our fly model. Despite minor differences in the actin 
binding properties, our data support a similar overarching conclusion that the S532P mutation 
affects actin binding.  
The ability of myosin to hydrolyze ATP in response to actin binding is necessary for 
normal progression through the chemomechanical cycle. The actin-stimulated ATPase activity 
(Vmax) of myosin isolated from Drosophila IFMs is consequently >6-fold higher in response to 
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actin binding relative to basal Mg-ATPase activity.76  We show here that the S532P mutation 
reduces actin-stimulated ATPase activity (Vmax) in absence of changes in basal Mg-ATPase 
activity, suggesting that impaired actomyosin interactions are responsible for the depressed 
motor function in the mutant. The actin binding affinity (Km) relative to the Vmax of ATPase was 
unaffected by the mutation. Skinned IFM fibers also exhibit reductions in actin-stimulated 
ATPase activity, suggesting similar effects of the mutation at the level of the muscle fiber. We 
postulate that the S532P mutation induces a conformational change that impairs closure of the 
actin binding cleft and slows Pi release. This is expected to lower the rate of transition from 
weak to strong actin binding77,78, consistent with our finding that apparent rate constants 2πb 
and 2πc are respectively lower and higher in skinned IFM mutant fibers. Similarly, a W546A 
mutation of chicken gizzard heavy meromyosin located within a helix structurally analogous to 
β-MyHC S532 dramatically lowers the Vmax of actin stimulated ATPase activity without altering 
Km.79 The authors suppose that the mutation interrupts actin cleft closure, slowing the rate of Pi 
release without affecting actin affinity. Consistent with our work, expression of the S532P 
mutation in human β-MyHC short subfragment-1 (sS1)74 and mouse α-MyHC30 lowered the Vmax 
of actin-stimulation, though the difference was not significant for α-MyHC.30 The Km of actin 
stimulation was significantly higher for human β-MyHC sS174, suggesting lower actin binding 
affinity, while Km was unchanged for α-MyHC.30 Discrepancies in ATPase parameters of these 
S532P myosins may arise from differences in myosin backbone, sample preparation, or whether 
full length or a myosin sub-fragment is tested. However, all share a common mechanism of 
impaired actomyosin interactions resulting in reduced actin-stimulated ATPase activity. 
Previous reports revealed that the S532P mutation reduces the loaded actin sliding 
velocity74 and force generating capacity8 of human β-MyHC sS1. Additionally, the maximum 
isometric force of S532P mouse α-myosin heavy chain was significantly reduced in a laser trap 
assay.80 Thus, we hypothesized that S532P myosin is underfunctional and that its expression in 
Drosophila would yield muscle functional deficits. S532P IFM fibers exhibit depressed power 
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production, and a reduction in the frequency at which maximum power was produced, 
suggesting slower overall muscle speed. Flight testing revealed progressive declines in skeletal 
muscle function, consistent with the progressive nature of reduced cardiac function in human 
DCM patients. The causes of functional decline with age remain unknown. Age-related changes 
in gene expression81-83, protein expression84, as well as damage to lipids, proteins85,86, and 
organelles85 may play a role in exacerbating muscle functional deficits. Ultrastructural properties 
of IFMs are normal in 3-week-old S532P/S532P flies, suggesting that the severe reductions in 
muscle function at this age are not due to structural deterioration of myofibrils. Similarly, the 
hypoactive A261T myosin mutation which lowers actin affinity, reduces actin-activated ATPase 
activity, causes defects in flight ability and yields cardiac dilation in Drosophila does not lead to 
structural deterioration of IFMs.59,87 Jump ability was also reduced in S532P/S532P flies but did 
not worsen with age. Though differences in protein backbone and muscle physiology are 
expected to influence the effects of the mutation, we expect that our data are relevant to 
disease mechanisms in cardiomyocytes since the mutation is located in a well-conserved actin-
binding site. Overall, our data support the hypothesis that depressed motor activity in S532P 
MHC reduces muscle function in Drosophila. 
We successfully produced the first Drosophila model of myosin-induced DCM and 
determined the mechanistic basis of disease. Drosophila is useful for classifying myosin 
cardiomyopathy mutations into those that either enhance or depress motor function.12,13 Since 
the S532P myosin form is underfunctional, treatment with a myosin activating drug may restore 
motor function of DCM myosin and prevent disease onset or progression. The small molecule 
omecamtiv mercarbil (OM) specifically binds and activates cardiac myosin by increasing the rate 
of Pi release, promoting a more rapid transition to the strong actin binding state.88,89 The 
duration of strong binding is also increased by OM, which enhances contractility in 
cardiomyocytes.74,90 OM is currently in phase 3 clinical trials for the treatment of systolic heart 
failure and is a promising drug candidate for the treatment of myosin-induced DCM.91,92 Future 
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work can exploit the Drosophila model as a platform for drug screening to provide insight into 
effective therapeutic interventions for human patients. 
Chapter 3, in full, contains unpublished material coauthored by Trujillo, Adriana S.; 
Puthawala, Joy; Hsu, Karen; Loya, Amy; Swank, Douglas; Bernstein, Sanford I. The dissertation 
author was the primary investigator and author of this chapter. 
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Chapter 4: Determine whether myosin DCM mutation S532P 
causes DCM in Drosophila 
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4.1. Introduction and hypothesis 
The goal of this aim is to determine if the Drosophila heart dilates in response to a 
mutation known to cause DCM in humans, to better understand the link between changes in 
myosin function and pathological cardiac remodeling. Drosophila contain an open circulatory 
system, with a simple tube-shaped heart that serves as a pressure pump. Hemolymph enters 
the heart through five sets of ostia cells. Active contraction of the heart in conjunction with the 
orchestrated opening and closing of ostia drives hemolymph flow anteriorly through a narrow 
aorta in the lower thorax.93 Retrograde pulses also pump hemolymph towards the posterior end 
of the abdomen to aid in diffusion for tracheal respiration. 
DCM patients exhibit enlargement of the cardiac chamber with frequent decreases in 
systolic function and thinning of cardiac walls.5,10 Systolic dysfunction involves inadequate 
emptying of the left ventricle (LV) that is characterized by reductions in ejection fraction (EF, 
forward stroke volume divided by end-diastolic volume) and fractional shortening (FS, the 
fraction of diastolic dimension lost during systole). For hereditary DCM, systolic dysfunction can 
result from mutations that produce cardiac contractile force deficits, including those that reduce 
actomyosin interaction.10 Cardiac dysfunction may be moderate to severe and histological 
findings are nonspecific but may include cardiomyocyte loss. Initially, LV enlargement is thought 
to involve a compensatory increase in blood volume pumped in the LV, which in turn increases 
ventricular stroke volume to preserve cardiac output via the Frank-Starling mechanism.94 
However, further LV dilation can cause pathogenic DCM, where the heart walls become thin 
and weak, causing force deficits and heart failure.95 
Here, we sought to determine whether our Drosophila model recapitulates clinical 
features observed in human DCM patients and in a murine DCM model. The age of diagnosis 
(ages 2-57) and severity of symptoms varied in 19 S532P/+ patients from a single family.5 
Nearly all patients exhibited clinically relevant enlargements in LV end-diastolic and systolic 
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diameters and some showed deficits in FS. In another family, 8 of 15 S532P/+ patients 
exhibited enlarged LV end-diastolic diameters and deficits in EF indicative of overt DCM.9 The 
effects of the S532P mutation are gene dose-dependent in mice, suggesting a disease 
causative role: heterozygous S532P/+ mice showed slowly progressing LV dilation and 
negligible changes in FS, while homozygous S532P/S532P mice showed rapid DCM 
progression and reduced FS. Based on these clinical features, we tested the hypothesis that 
expression of S532P myosin in Drosophila will cause cardiac contractile defects, leading to 
pathological remodeling akin to the human condition (i.e., cardiac dilation) in a gene dose-
dependent fashion. In support of our hypothesis, Cammarato et al.59 showed that a point 
mutation (A261T/D45) in Drosophila Mhc that reduces its enzymatic activity87 also causes 
cardiac dilation compared to wild-type (yw) hearts. Using a cardiac physiological analysis, these 
studies demonstrated that the Drosophila heart can dilate in response to a myosin mutation. 
However, it was previously unknown whether the Drosophila heart dilates in response to a 
human DCM myosin mutation. To test this, we determined the cardiac physiological and 
ultrastructural defects observed in Mhc S532P flies.  
4.2. Materials and methods 
4.2.1. Cardiac physiological analysis 
Beating, intact hearts from female flies were surgically exposed in oxygenated artificial 
hemolymph and recorded for 30 seconds using a high-speed, high-resolution video camera 
(Hamatsu Orca Flash 2.8 CMOS or AOS Promon U750) on a light microscope with a 10x 
immersion lens. Functional parameters were determined using a Matlab-based semi-automatic 
heartbeat analysis software.96,97 For each video, heart chamber dimensions were marked during 
peak diastole (relaxation) and peak systole (contraction). This was used to determine diastolic 
(DD) and systolic diameters (SD). Diastolic and systolic diameters were also utilized to calculate 
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fractional shortening (FS), to determine heart contractility, using the following equation: FS = 
(DD-SD)/(DD). M-mode diagrams were obtained to reflect contractile parameters from single 
pixel tracings of heart wall movements (Fig. 4.1). Parameters related to contractile dynamics 
included durations for diastolic interval, systolic interval, and heart period (diastolic + systolic 
interval). At least 30 hearts per genetic line were examined for these parameters and the mean 
values for each parameter were statistically compared to controls using a one-way or two-way 
ANOVA.  
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Figure 4.1- A schematic representation of the cardiac physiological analysis 
Hearts were surgically exposed in oxygenated artificial hemolymph. High-speed videos of 
beating hearts were recorded for 30 seconds. For each video, heart chamber dimensions were 
marked during diastole (relaxation) and systole (contraction). This was used to determine 
diastolic (DD) and systolic diameters (SD). Diastolic and systolic diameters were also utilized to 
calculate fractional shortening (FS), to determine heart contractility. To generate M-modes, a 1 
pixel-width slice of the video was displayed over time. A representative 5 second portion of an 
M-mode from a 3 week-old PwMhc2 heterozygous control is shown. Full genotype is PwMhc2/-; 
Mhc1/+, where “-“ indicates there is no P element on the homologous chromosome. The orange 
line marks the region where M-modes were derived. M-modes were used to calculate 
parameters relating to contractile dynamics, including diastolic interval (DI), systolic interval (SI), 
and heart period (DI + SI). 
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4.2.2. Cardiac ultrastructural analysis 
The dorsal vessel including the heart was dissected from 4-day old homozygotes. 
Normal, rhythmic beating was verified to avoid analysis of structurally perturbed hearts. Hearts 
were bathed with a relaxing solution containing 10 mM EGTA and prepared for TEM, as 
described in Section 3.2.6. 
Transverse thin sections of heart tubes were obtained to determine average cardiac 
thickness, as previously described.12 For each measurement, a rectangular area of the 
cardiomyocyte tissue of 10 µm in length and spanning the distance from the inner to outer 
cardiac cell wall was highlighted using Adobe Photoshop. The image was imported into NIH 
ImageJ to calculate the area of the highlighted region. The resulting area was divided by 10 µm 
to yield the average cardiomyocyte thickness for that highlighted region. Cardiomyocyte 
thickness measurements from dorsal-side or ventral-side images were averaged among 
biological replicates. 
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4.3. Results 
4.3.1. Cardiac physiological analysis 
To determine the effects of the S532P mutation on cardiac physiology, non His-tagged 
Mhc S532P transgenic flies (see Chapter 3) were crossed into the Mhc1 background. The Mhc1 
allele is null for endogenous myosin in all muscles and must be maintained over a balancer 
chromosome to permit viability.98 Two copies of the Mhc S532P transgene rescued lethality of 
the Mhc1 homozygotes. Hence, we were able to examine the effects of the mutation in 
homozygotes, as well as in heterozygotes (akin to the human condition). Since a majority of 
homozygotes were not viable beyond the first 4 days of age, only young homozygotes were 
examined. Aged heterozygotes were viable, permitting the comparison of physiological 
parameters between young and aged heterozygotes. 
Young 4 day-old S532P/+ flies exhibited no differences in diastolic (DD) and systolic 
(SD) diameters (Fig. 4.2), as well as parameters related to contractile dynamics (Fig. 4.3) [e.g. 
heart period (HP), systolic interval (SI), and diastolic interval (DI)] relative to controls. Although 4 
day-old S532P-L1/+ flies displayed reduced fractional shortening (FS) compared to controls (% 
FS ± S.E.M, P value: 0.296 ± 0.010 vs. 0.341 ± 0.009, P= 0.0032), FS did not differ for the other 
two lines tested (Fig. 4.2). Thus, overall cardiac output was maintained in young S532P/+ flies. 
Age-associated decreases in DD were observed in controls from ages 4 days (74.728 ± 1.315 
μm) to 3 weeks (67.209 ± 1.262 μm). However, DD did not change with age in S532P/+ lines. 
Consequently, aged 3 week-old S532P/+ flies exhibited a dilated phenotype, characterized by 
significantly higher DD compared to controls (74.202 ± 1.327, 74.796 ± 1.479, and 74.934 ± 
0.889 μm vs. 67.209 ± 1.262 μm). Two-way ANOVAs demonstrated significant differences 
between control and mutant lines (p<0.01), while the effects of age as an independent factor 
were not statistically significant. Though there was a statistically significant interaction between 
age and genotype (p<0.01), this could be explained by the decrease in diastolic diameters 
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observed in controls with age, rather than a progressive dilation with age in mutant lines. The 
mutational effect on DD in absence of changes in SD resulted in increased FS relative to 
controls at 3 weeks of age (0.390 ± 0.009, 0.383 ± 0.008, and 0.377 ± 0.007 vs. 0.334 ± 0.010). 
The effects of genotype (p<0.05) and age (p<0.0001) as two independent factors, as well as the 
interaction between age and genotype (p<0.0001), contribute to statistically significant 
differences between groups. 
Contractile dynamics were also altered in S532P/+ mutants (Fig. 4.3). Control flies 
displayed an age-associated increase in HP, which is the length of time required for the 
completion of a single diastolic and systolic event, from 4 days (0.542 ± 0.037 sec) to 3 weeks 
(1.392 ± 0.078 sec) of age. DI also increased in controls from 4 days (0.323 ± 0.033 sec) to 3 
weeks (1.166 ± 0.075 sec) of age. S532P/+ mutant lines L1 and L3 did not exhibit age-
associated changes in HP and DI. The durations of HP (0.546 ± 0.044, 0.466 ± 0.033, and 
0.495 ± 0.021 sec vs. 1.392 ± 0.078 sec) and DI (0.375 ± 0.042, 0.313 ± 0.030, and 0.297 ± 
0.020 sec vs. 1.166 ± 0.075 sec) were significantly lower in 3 week-old S532P/+ flies compared 
to controls, suggesting that heart rhythm is enhanced in mutants. S532P/+ lines L1 and L2 
displayed age-associated decreases in SI, while controls did not differ with age. Significant 
reductions in SI were observed in all three S532P/+ lines compared to controls at 3 weeks of 
age (0.171 ± 0.008, 0.153 ± 0.004, and 0.199 ± 0.004 sec vs. 0.228 ± 0.007 sec). The effects of 
genotype (p<0.0001), age (p<0.0001), and an interaction effect (p<0.0001) contribute to 
differences in HP, DI, and SI between groups. A reduction in SI suggests that expression of the 
S532P mutation reduces the duration of the portion of the cardiac cycle in which active tension 
is produced, which is consistent with our hypothesis that this mutation reduces myosin function. 
However, given that aged S532P/+ flies also display increases in contractility and heart rhythm, 
overall cardiac output is elevated compared to controls.  
To determine if expression of two copies of the mutant transgene causes more severe 
cardiac physiological abnormalities, homozygous S532P mutants were crossed into a 
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Mhc1/Mhc1 background. Both S532P homozygous lines tested (L1 and L2) exhibited a dilated 
phenotype, characterized by increases in DD compared to controls (Fig. 4.4) (82.805 ± 1.095, 
p<0.0001 and 75.124 ± 1.675 μm, p<0.05 vs. 70.448 ± 1.965 μm). Line L1 exhibited increased 
SD (60.624 ± 1.215 μm vs. 47.764 ± 2.038 μm, p<0.0001) and decreased FS (0.268 ± 0.011 vs. 
0.328 ± 0.013, p<0.001), while line L2 did not show differences in these parameters relative to 
controls. Line L1 also showed a reduction in heart period compared to controls (0.466 ± 0.031 
sec. vs. 0.593 ± 0.041 sec., p<0.05), while the other line tested (L2) did not. Diastolic and 
systolic intervals did not differ in both mutant lines compared to controls. Since young 
homozygotes displayed a dilated phenotype, while age-matched heterozygotes did not, the 
mutational effects on cardiac dilation were gene dose-dependent in our fly models. 
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Figure 4.2- Cardiac physiological parameters of S532P/+ lines, Part I 
Cardiac diameters (A-B) and fractional shortening (C) values of 4 day-old or 3 week-old 
PwMhc2 control or mutant S532P heterozygous lines (L1 or L2) crossed into a heterozygous 
Mhc1-null background. Full genotypes are shown in parenthesis, where “-“ indicates there is no 
P element on the homologous chromosome: S532P/+ lines (Mhc1/+; P[S532P]/-); PwMhc2/+ 
transgenic controls (P[PwMhc2]/-; Mhc1/+). Values represent mean ± S.E.M. Two-way ANOVAs 
were employed to test if the effects of genotype and age were significant for each cardiac 
parameter investigated (*p<0.05, **p<0.01, ****p<0.0001, and ns= non-significant). 
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Figure 4.3- Cardiac physiological parameters of S532P/+ lines, Part II 
Heart period (A), diastolic interval (B), and systolic interval (C) of 4 day-old or 3 week-old 
PwMhc2 control or mutant S532P heterozygous lines (L1 or L2) crossed into a heterozygous 
Mhc1-null background. Full genotypes are shown in parenthesis, where “-“ indicates there is no 
P element on the homologous chromosome: S532P/+ lines (Mhc1/+; P[S532P]/-); PwMhc2/+ 
transgenic controls (P[PwMhc2]/-; Mhc1/+). Values represent mean ± S.E.M. Two-way ANOVAs 
were employed to test if the effects of genotype and age were significant for each cardiac 
parameter investigated (*p<0.05, **p<0.01, ****p<0.0001, and ns= non-significant). 
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Figure 4.4- Cardiac physiological parameters of S532P/S532P lines 
Cardiac dimensions (A-B), fractional shortening (C), and dynamics (D-F) of 4 day-old PwMhc2 
control or mutant S532P homozygous lines (L1 or L2) crossed into a homozygous Mhc1-null 
background. Full genotypes are shown in parenthesis: S532P lines (Mhc1/Mhc1 ; 
P[S532P]/P[S532P]); PwMhc2 transgenic controls (P[PwMhc2]/P[PwMhc2]; Mhc1/Mhc1). Values 
represent mean ± S.E.M. One-way ANOVAs determined statistical significance compared to 
controls, where *p<0.05, ***p<0.001, ****p<0.0001, and ns= non-significant.  
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4.3.2. Cardiac ultrastructural analysis 
Transmission electron microscopy (TEM) was employed to determine if the S532P 
mutation affects cardiac ultrastructure. Micrographs of thin sections across the heart tube reveal 
a layer of cardiac myocytes as well as a layer of supportive ventral-longitudinal skeletal muscle 
cells (Fig. 4.5 A-B). Cardiac myofibrils (MF) are oriented mainly perpendicular to the anterior-
posterior axis and contain discontinuous Z-disks (arrows), as standardly observed in this 
tissue.12,13,99-101 The ultrastructure of 4 day-old S532P homozygous mutant hearts are similar to 
controls, with no obvious signs of myofibrillar disorganization, assembly defects, or 
degeneration. Dorsal-side and ventral-side cardiac thickness averages do not differ in 4 day-old 
homozygous mutants compared to controls (Fig. 4.5 C-D). Taken together with the cardiac 
physiology data, S532P hearts do not show obvious signs of progressive, pathological DCM 
remodeling, but do exhibit a dilated phenotype similar to human DCM hearts. 
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Figure 4.5- Cardiac ultrastructure of S532P lines 
(A-B) Transmission electron micrographs of hearts of 4 day-old PwMhc2 control or mutant line 
S532P-L1 in a homozygous Mhc1-null background. Full genotypes are shown in parenthesis: 
S532P lines (Mhc1/Mhc1 ; P[S532P]/P[S532P]); PwMhc2 transgenic controls 
(P[PwMhc2]/P[PwMhc2]; Mhc1/Mhc1). Micrographs show transverse sections of the heart tube 
between the third and fourth sets of ostia. MF-myofibril. M- mitochondrion. VL- supportive 
ventral-longitudinal fibers. Scale bar, 0.5 µm. C-D) Cardiac thickness of dorsal-side (C) and 
ventral-side (D) areas of the heart were measured using ImageJ. Values represent mean ± 
standard deviation. Student’s t-tests determined statistical significance compared to controls, 
where ns= non-significant.  
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4.4. Discussion 
To explore tissue-level alterations in cardiac function and structure induced by the 
S532P myosin mutation, we crossed non His-tagged genomic mutant lines into the Mhc1 myosin 
null background.98 Cardiac physiological parameters were assessed in S532P/+ and 
S532P/S532P flies to test the hypothesis that expression of a myosin DCM mutation would lead 
to cardiac dilation in Drosophila. We predicted that mutant flies would exhibit clinical features of 
DCM patients, including enlarged diastolic and systolic diameters as well as reduced fractional 
shortening.5,10 We also predicted that DCM would arise from cardiac remodeling, similar to 
disease progression in humans.102  
Though some physiological properties of S532P flies were unexpected (including 
elevated contractility and heart rhythm in aged S532P/+ flies), young 4 day-old S532P/S532P 
and aged 3-week-old S532P/+ flies did exhibit a dilated phenotype. However, cardiac dilation in 
S532P/+ flies did not result from progressive enlargement of diastolic diameters (DD). Controls 
exhibited an age-associated reduction of DD, while S532P/+ flies did not, which produced a 
statistically significant difference in DD between genotypes at 3 weeks of age. Similarly, age-
associated reductions in heart chamber dimensions were previously reported in wild-type100,103 
and transgenic non-mutant experimental control flies104. Since older flies exhibit altered calcium 
dynamics105 and ion channel function106, we speculate that altered calcium handling plays a role 
in impaired relaxation with age in controls. Both mutants and controls exhibited progressive 
narrowing of systolic diameters with age, and no differences were observed between 
genotypes. The mutational effect on DD in absence of changes in SD resulted in enhanced FS 
in aged S532P/+ flies. Young S532P/+ flies did not exhibit differences in FS compared to 
controls, suggesting that cardiac dilation in older S532P/+ flies does not compensate for 
contractile dysfunction in young flies. The cardiac dilation exhibited by our fly model is also gene 
dose-dependent, since young 4-day-old S532P/S532P flies exhibited larger diastolic diameters 
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relative to controls, while age-matched S532P/+ flies did not. Similarly, S532P/S532P mice 
exhibited more severe cardiac dilation compared to S532P/+ mice.30 Contractile deficits were 
reported in isolated mouse α-MyHC S532P cardiomyocytes at an age prior to cardiac dilation, 
suggesting an association between cardiac dilation and systolic dysfunction in mice.30 However, 
systolic dysfunction was absent in our fly model, since aged S532P/+ or young S532P/S532P 
flies did not exhibit deficits in contractile performance. It is possible that the dilated phenotype 
allows aged S532P/+ mutant flies to preserve contractility in response to cell death or other cell 
stressors induced by the S532P mutation. Since the P element transgene is expressed in all 
muscles, such stressors may affect the heart in a cell autonomous or cell non-autonomous 
fashion. This may result in overall changes in gene expression that alter calcium handling and 
heart relaxation in mutants, inhibiting the age-associated reduction in DD. 
Contractile dynamics were also altered in aged S532P/+ flies. An age-associated 
increase in heart period (i.e. decrease in heart rate) was observed in PwMhc2/+ controls from 
ages 4 days to 3 weeks. Similarly, age-associated reductions in heart rate were previously 
reported in older flies and were linked to impaired relaxation caused by a longer Ca2+ decay 
time105 or electrophysiological defects.107 Additionally, altered expression of genes controlling 
cardiac ion channel function106, metabolism82,108, protein synthesis83, and protein folding83 may 
further influence heart rate decline with age. Heart period did not change with age in S532P/+ 
flies. Thus, heart period was significantly lower in aged mutant hearts compared to controls, 
which was associated with reductions in both diastolic and systolic intervals. Since aged 
mutants exhibit elevated heart rhythmicity and contractility, overall cardiac output is higher in 
mutants. It is possible that S532P/+ flies compensate for contractile deficits during development 
or cell stressors by altering one or more gene expression pathways that inhibit heart rate decline 
and preserve cardiac output. The systolic interval (i.e. contraction interval) was lower in aged 
S532P/+ flies, suggesting that the mutation decreases the duration of the cardiac cycle in which 
active tension is generated. Since muscle rate apparent constants related to actin binding (2πb) 
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and dissociation (2πc) are respectively increased and decreased in IFMs, we suppose that 
impaired actomyosin interactions could result in shortened contractions in the heart as well. 
We previously reported degeneration of myofibrils in IFMs and hearts of flies expressing 
hyperactive mutant myosins associated with human restrictive13 and hypertrophic12 
cardiomyopathy. Excessive cross-bridge binding was proposed to cause hypercontractility and 
subsequent deterioration of cardiac myofibrils in the latter.12 In contrast, cardiac ultrastructural is 
normal in 4-day-old S532P/S532P flies, suggesting that cardiac physiological abnormalities 
induced by the hypoactive S532P myosin form are not caused by defects in myofibrillar 
assembly or maintenance. This is consistent with our data that IFM ultrastructure is normal in 
S532P/S532P flies (chapter 3). Similarly, flies expressing the hypoactive A261T myosin 
mutation displayed normal IFM ultrastructure despite having reduced muscle function.59 
Cardiomyocyte disarray was also absent in a S532P/+ patient5 and in α-MyHC S532P mice.30 
Unlike human DCM, our fly model did not exhibit signs of pathological cardiac remodeling. 
Given that heart diameters did not get progressively larger with age in S532P/+ flies, it is 
unlikely that expression of this mutation results in eccentric hypertrophy (addition of sarcomeres 
in series).109 We note that it is not feasible to assess for eccentric hypertrophy in TEM 
micrographs due to the spiraling nature of the myocytes, which harbor discontinuous Z-disks.110 
In humans, a switch to pathological DCM involves myocyte cell loss and the progressive 
thinning of cardiac walls.109 Cardiac thickness did not differ in S532P/S532P flies compared to 
controls, suggesting that cardiac dilation is not associated with a loss of cardiac myofibrils. 
Though Drosophila is useful for modeling the effects of myosin mutations on cardiac 
structure and function, some limitations in our model do exist. Differences in the amino acid 
backbone between Drosophila MHC and human β-MyHC may influence the biochemical effects 
of the mutation. However, since the S532P mutation is located in a structurally conserved actin 
binding region of the motor domain74,111, we expect some of its effects on cardiac structure and 
function in Drosophila to be relevant to human disease. Though the molecular mechanisms of 
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muscle contraction are similar between Drosophila and human hearts, phenotypic outcomes 
may vary between species due to differences in cardiac morphology and physiology.97,112,113 In 
our fly model, non-cell autonomous stressors may affect the heart, since the P element 
transgene is expressed in all muscles. Since human β-MyHC is primarily expressed in the left 
ventricle, it is probable that the effects of myosin DCM mutations on left ventricular systolic 
dysfunction in humans are cell autonomous. Human patients exhibit changes in the proportions 
of α-MyHC and β-MyHC with heart failure114, while it is not known whether MHC isoform 
switching occurs in Drosophila hearts. Furthermore, additional gene mutations are thought to 
influence the phenotypic variation of human DCM patients10, while our Drosophila model is 
isogenic. Thus, we expect some differences in the etiology of DCM in humans compared to fly 
models. 
Despite these limitations, Drosophila is useful for determining the mechanistic basis of 
myosin-induced DCM. There are several advantages of using Drosophila as a model over mice, 
including their low maintenance costs, short generation time, high fecundity, and the ability to 
generate a transgenic model more efficiently.14 Additionally, Drosophila can sustain viability with 
limited heart function, contrary to mice.113 Furthermore, the effects of the mutation on cardiac 
function in homozygous flies can be assessed independently without compensation by wild-type 
myosin, since the nucleotide change corresponding to the S532P mutation is in a constitutive 
exon that is expressed in all protein isoforms. Since mice express more than one cardiac 
isoform115, it is possible that non-mutant myosin partially compensates for functional defects 
induced by the mutation in mice. The Drosophila system is also advantageous over in vitro cell 
models due to the ability to perform tissue-level assessments.12,13 Our novel fly model provides 
a better understanding of the structural, biochemical, and biophysical properties of mutant DCM 
myosin (chapters 2 and 3), and its effects on muscle structure and function (chapters 3 and 4). 
Since DCM patients with myosin mutations can harbor mutations in other genes important for 
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muscle function22, Drosophila may provide an efficient screening system to predict which 
mutation(s) are causative of disease.  
The successful generation of models that recapitulate human disease phenotypes may 
provide insight into effective therapeutic treatments for human patients. In Drosophila, the 
cardiac physiological response to drug treatment can be readily assessed on semi-intact heart 
preparations.12,116 Future directions will exploit our model to screen for pharmacological agents 
aimed at ameliorating cardiac defects induced by DCM myosin. Treatment with the cardiac 
specific myosin activating drug omecamtiv mercarbil (OM), which accelerates the Pi release88,89 
and increases the duration of strong actomyosin binding90, is a promising drug candidate in this 
regard. 
Chapter 4, in full, contains unpublished material coauthored by Trujillo, Adriana S.; 
Viswanathan, Meera; Cammarato, Anthony R.; Bernstein, Sanford I. The dissertation author 
was the primary investigator and author of this chapter. 
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Chapter 5: Determine the importance of a conserved R369 actin 
binding residue of myosin affiliated with DCM 
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5.1. Introduction and hypothesis 
The goal of this aim is to elucidate the importance of conserved β-MyHC residue that 
has been mutated in a pediatric DCM patient. This patient exhibited lateral and posterior left 
ventricular (LV) noncompaction, LV dilation, and contractile deficits.117 Genetic testing revealed 
a G→A transition at nucleotide position 1106 of MYH7, resulting in an arginine to glutamine 
substitution. The β-MyHC R369 residue (Fig. 5.1- green; D. melanogaster MHC R368) faces the 
outside of the molecule within a loop near known actin-binding residues (red). Based on the 
location of the residue, it may directly interact with actin during the contractile cycle or indirectly 
modulate actin binding by influencing the orientation of actin binding residues. A cryo-EM 
structure of the actin/tropomyosin/myosin complex incorporating the crystal structure of 
Dictyostelium myosin-IE54 revealed that this residue directly interacts with the SD3 region of 
actin in the rigor state. Molecular dynamics simulations incorporating the actomyosin cryo-EM 
complex in conjunction with X-ray structures for F-actin and chicken skeletal muscle myosin II 
predicted that MHC S1 binds actin at the R371 residue, which is homologous to β-MyHC 
R369.31 Furthermore, in Dictyostelium myosin II, mutation of the entire loop containing this 
residue to glycine residues led to weakened actin binding.118 
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Figure 5.1- The location of the R369 myosin residue within an actin binding region of the 
motor domain 
The β-MyHC R369 residue (green) was modeled on the crystal structure of chicken skeletal 
muscle myosin II in the post-rigor configuration (PDB ID: 2MYS). Red- actin binding sites. 
Yellow- ATP binding pocket. 
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Given that the R369 residue resides within the actin binding region of the motor domain 
and is predicted to interact directly with actin, we assessed the effects of mutating this residue in 
the Drosophila system by substituting a histidine residue. This mutation retains the positive 
charge of the wild-type residue, but introduces a bulky imidazole ring that may sterically hinder 
an electrostatic interaction with the SD3 region of actin. Thus, we hypothesized that the R369H 
mutation would disrupt a direct interaction with actin, weaken actin affinity, and reduce myosin 
function. To test this hypothesis, we generated fly models to determine the importance of the 
R369 residue interaction with actin. 
5.2. Materials and methods 
5.2.1. Generation of a mutant His-tagged myosin line and protein 
purification 
We generated a His-tagged line for bulk myosin isolation from IFMs, as described in 
Section 2.2.1. For this, we utilized a non-mutant pAttB 6HisIFI plasmid previously produced by 
our lab, which contains the IFM-specific Actin-88F promoter, an amino-terminal His-tag, a 
tobacco etch virus (TEV) protease recognition site (for removal of the His-tag), cDNA encoding 
the IFI motor domain, as well as genomic DNA encoding MHC exons 12-19 along with their 
affiliated introns and polyadenylation sites. The cloning strategy is shown in Fig. 5.2. For the first 
two steps, subclones containing Mhc exon 8 were generated from the larger plasmid. 
Oligonucleotide-directed mutagenesis was performed (QuikChange kit, Stratagene) to change 
the codon in Drosophila Mhc that corresponds to the R369H mutation. The following forward (+) 
and the reverse (-) primers were used: 
(+): 5'-CAAGCAACGTGGTCACGAGGAGCAGGCTG-3' 
(-): 5'-CAGCCTGCTCCTCGTGACCACGTTGCTTG-3' 
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The mutated exon was sequenced for confirmation and inserted into a larger cloning 
intermediate. The entire construct was removed and ligated into a pAttB vector containing a  
miniwhite (w+) selectable eye color marker that restores eye color in a white-eyed genetic  
background, as well as PhiC31 integrase AttB recognition sites. The final clone was purified 
using the QIAfilter Plasmid Maxi Kit (Qiagen Inc.) and sequenced for verification by Eton 
Bioscience. Targeted insertion was performed by Bestgene Inc. using the PhiC31-mediated 
transgenesis system.44 One transgenic line containing a third chromosome targeted insert was 
produced. 
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Figure 5.2- Cloning scheme for the 6HisIFI R369H construct 
The sequential steps of restriction enzyme (RE) digestion and ligation are shown by the blue 
arrows. Each insert generated by RE digestion of the parent vector is shown in red, along with 
RE cut sites. Site-directed mutagenesis (black arrow) was performed to change the encoded 
arginine residue to a histidine residue at the 368th amino acid coding position of Drosophila Mhc 
(corresponding to position 369 in human MYH7). The mutant construct was ligated into a pAttB 
vector for targeted insertion by Bestgene, Inc using the PhiC31 transgenesis system.  
 
99 
Transgenic flies were crossed into a Mhc10 background that is null for endogenous 
myosin in IFMs.45 Myosin protein levels are expressed at ~80% relative to wild-type yw flies in 
upper thoraces, as determined by SDS-PAGE and densitometry analysis.46 RT-PCR was 
performed to verify that the Mhc transcripts produced by this line contain the appropriate 
nucleotide transition. For this, RNA was isolated from 2 day-old upper thoraces using the 
RNeasy kit by Qiagen, Inc. The Protoscript cDNA synthesis kit was employed to generate 
cDNAs, using 500 ng RNA and 100 ng of the specific reverse (-) primer shown below. The 
following primers were used for PCR amplification:  
(+) 5’-TGGATCCCCGACGAGAAGGA-3’ 
(-) 5’-GTTCGTCACCCAGGGCCGTA-3’ 
 
The (-) end directed primer was used to generate cDNAs.  
Bulk isolation of His-tagged mutant IFI and subsequent purification of the mutant motor 
domain was performed as described in Section 2.2.2. 
5.2.2. Generation of mutant (non His-tagged) genomic DNA lines 
Subclones containing Mhc exon 8 were generated from a larger plasmid containing a 
19.2 kb Mhc 5’ fragment (Fig. 5.3). Oligonucleotide-directed mutagenesis was performed 
(QuikChange kit, Stratagene) to change the codon in Drosophila Mhc that corresponds to the 
R369H mutation. The following forward (+) and reverse (-) primers were used for mutagenesis: 
(+): 5'-CAAGCAACGTGGTCACGAGGAGCAGGCTG-3' 
(-): 5'-CAGCCTGCTCCTCGTGACCACGTTGCTTG-3' 
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Figure 5.3- Cloning scheme for the non his-tagged Mhc R369H construct, Part I 
The sequential steps of restriction enzyme (RE) digestion and ligation are shown by the blue 
arrows. Each insert generated by RE digestion of the parent vector is shown in red, along with 
RE cut sites. Site-directed mutagenesis (black arrow) was performed to change the arginine 
residue to a histidine residue at the 368th amino acid coding position of Drosophila Mhc 
(corresponding to position 369 in human MYH7).  
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The mutated exon was sequenced for confirmation and subclones containing the mutant 
fragment were inserted into larger cloning intermediates to produce the mutant 5’ Mhc fragment. 
For the final cloning step, a 19.2 kb 5’ Mhc fragment carrying the R369H mutation was removed 
from its vector by EagI digestion, and ligated to a 3’ Mhc fragment in a pCaSpeR P element 
vector containing the miniwhite (w+) selectable eye color marker (Fig. 5.4). The final clone was 
purified using the QIAfilter Plasmid Maxi Kit (Qiagen Inc.) and the entire Mhc coding region was 
sequenced for verification by Eton Bioscience.  
Embryonic injection was performed by Bestgene, Inc. to incorporate the transgenic insert 
randomly into the germline via P element transformation.44 A total of 20 transgenic lines were 
obtained. Several lines mapping to the 3rd chromosome were crossed into the Mhc10 myosin-
null background. Lines that mapped to the second chromosome were not used since it contains 
the endogenous Mhc gene.  
Polyacrylamide gel electrophoresis was performed to determine MHC protein levels in 
these lines, by comparing the ratio of myosin to actin between transgenic flies and yw (wild-
type) controls, as described previously.46 Each lysate consisted of six upper thoraces of 0-2 
day-old flies. Only lines with wild-type MHC protein levels were chosen for further experiments.  
  
 
102 
 
Figure 5.4- Cloning scheme for the non his-tagged Mhc R369H construct, Part II  
A 19.2 kb 5’ Mhc fragment carrying the R369H mutation was removed from its vector by EagI 
digestion, and ligated to a Mhc 3’ fragment in a pCaSpeR P element vector. 
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RT-PCR confirmed expression of RNA encoding the mutant protein and the absence of 
endogenous myosin expression in IFMs. Additionally, cDNA was amplified using Mhc specific 
primers to confirm the absence of alternative splicing defects in these lines. RNA isolation, 
cDNA synthesis, and PCR amplification were performed as described in Section 3.2.2., using 
the following primer pairs: 
Exons 2-8:  
(+) 5’-TGGATCCCCGACGAGAAGGA-3’ 
(-) 5’-GTTCGTCACCCAGGGCCGTA-3’ 
Exons 8-12:  
(+) 5’-TCTGGATACCCAGCAGAAGCGT-3’ 
(-) 5’-GAGCTTCTTGAAGCCCTTACGG-3’  
Exon 15:  
(+) 5’-CTCAAGCTCACCCAGGAGGCT-3’ 
(-) 5’-GGGTGACAGACGCTGCTTGGT-3’ 
For simplicity, lines R369H-1, R369H-16, and R369H-6 were respectively renamed as 
R369H-L1, R369H-L2. and R369H-L3. 
5.2.3. Biochemical assays 
The actin co-sedimentation assay was performed as described in Section 3.2.1. The 
ATPase assay was performed as described in Section 3.2.3.  
5.2.4. Organismal tests 
Flight and jump tests were performed as described in Section 3.2.5. Transmission 
electron microscopy of skeletal muscles and cardiac muscles was performed as described in 
Sections 3.2.6 and 4.2.2. The cardiac physiological analysis was performed as described in 
Section 4.2.1. 
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5.3. Results 
5.3.1. Actin co-sedimentation 
The binding affinity of R369H S1 for F-actin was determined using the co-sedimentation 
approach. Increasing concentrations F-actin were incubated with a fixed concentration of control 
or R369H S1. Following high speed centrifugation, S1 remained soluble in S1-only controls, 
while F-actin was insoluble in F-actin-only controls (Fig. 5.5A). SDS-PAGE gels of centrifuged 
samples were scanned and densities of S1 bound fractions were fit to a hyperbolic function to 
determine the Bmax and dissociation constant (Kd) for F-actin (Fig. 5.5B).  R369H S1 exhibited a 
significantly lower Bmax value compared to control S1 (0.597 ± 0.085 vs. 1.024 ± 0.211, P= 
0.03), indicating reduced maximal binding to F-actin in vitro. Values for Kd did not significantly 
differ for mutants compared to controls (1100 ± 510 nM vs. 1260 ± 963 nM, P= 0.81).  
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Figure 5.5- Co-sedimentation of R369H IFI S1 and control IFI S1 for F-actin 
A) A representative SDS-polyacrylamide gel showing insoluble pellet (P) fractions of F-actin and 
IFI S1-containing samples over increasing F-actin concentrations (Lanes 5-15: 0.4, 0.6, 0.8, 1, 
1.2, 1.4, 1.6, 1.8, 2, 3, and 4 μM). Supernatant (S) and pellet (P) fractions of samples containing 
S1 or F-actin alone are shown as controls (Lanes 1-4). B) The bound fractions in actomyosin-
containing samples were determined via densitometry and plotted vs. F-actin concentration. To 
determine bound fractions, the density of S1 in the pellet fraction relative to total protein content 
was calculated, and the fraction of pelleted S1 in a S1-only control was subtracted from this 
value. Data are reported as mean ± SD. To determine actin binding affinity, the dissociation 
constant of S1 for F-actin (Kd ) was defined as the F-actin concentration required to reach half 
maximal binding (Bmax). 
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5.3.2. Fly line validation 
To study the biochemical and physiological effects of the R369H mutation, we used P 
element transformation to engineer fly lines harboring the R369H myosin mutation lacking a His-
tag. Since lines produced by P element transformation can exhibit position effects due to the 
chromosomal site of insertion, we produced multiple transgenic lines to ensure reproducibility of 
in vivo functional analyses. A total of 20 transgenic lines were obtained. Lines mapping to the 
third chromosome were crossed into the Mhc10 genetic background that is null for endogenous 
myosin in IFMs and jump muscles.45 
To pursue our study, we selected fly lines with wild-type myosin to actin levels, as 
determined by SDS-PAGE analysis of upper thoraces of young mutant flies (Table 5.1). RT-
PCR of IFM lysates from these lines confirmed expression of RNA encoding mutant myosin, the 
absence of endogenous myosin expression, and the absence of alternative splicing defects in 
these lines (Table 5.1).  
Table 5.1- Validation of R369H fly lines 
Protein expression levels in IFMs from R369H lines (L1, L2, and L3) relative to wild-type yw flies 
were determined using densitometry. Data are reported as mean ± SEM. RT-PCR of RNA 
isolated from IFMs was performed to verify that each line expresses transcripts encoding mutant 
myosin in absence of endogenous myosin, and to verify that alternative exon splicing was not 
disrupted. ✓ represents verification of the mutation or normal IFI alternative exon. 
 
5.3.3. ATPase assay 
Steady state ATPase parameters of myosins prepared from dissected IFMs were 
assessed to determine if the R369H mutation affects the enzymatic activity of myosin (Fig. 5.6). 
Ca-ATPase as well as basal Mg-ATPase activities did not significantly differ between R369H 
and transgenic wild-type myosin (PwMhc2) myosin.  Furthermore, the Vmax (maximum ATPase 
Genotype Protein 
expression 
Mutation 
present 
Exon 
3b 
Exon 
7d 
Exon 
9a 
Exon 
11e 
Exon 
15a 
R369H-L1 95.3 ± 2.4 ✓ ✓ ✓ ✓ ✓ ✓ 
R369H-L2 105.4 ± 3.4 ✓ ✓ ✓ ✓ ✓ ✓ 
R369H-L3 104.6 ± 2.1 ✓ ✓ ✓ ✓ ✓ ✓ 
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rate) of actin-stimulation, as well as the affinity constant (Km) of actin required to reach 50% Vmax 
did not differ for R369H relative to control myosin. 
5.3.4. Flight and jump tests 
Mutant lines were tested for flight and jump muscle function compared to PwMhc2 (P 
element-transformed wild-type) controls to determine if the R369H mutation causes tissue level 
muscle functional defects (Fig. 5.7). Homozygous mutant lines (L1-L3) displayed reduced flight 
ability compared to controls at ages 2-days [arbitrary units (A.U.) ± S.E.M: 2.72 ± 0.21, 1.14 ± 
0.14, and 0.52 ± 0.09 vs. 3.70 ± 0.15 A.U.], 1-week (2.30 ± 0.22, 0.82 ± 0.09, and 0.32 ± 0.07 
vs. 3.52 ± 0.12 A.U.), and 3-weeks (0.90 ± 0.14, 0.42 ± 0.08, and 0.22 ± 0.06 vs. 3.32 ± 0.13 
A.U.) (Fig. 5.7A). Two-way ANOVAs determined that the effects of genotype (p<0.0001) and 
age (p<0.0001) as two independent factors, as well as the interaction between age and 
genotype (p<0.0001), contribute to statistically significant differences between groups. Thus, the 
R369H mutation causes defects in flight ability that are progressive with age. We also assessed 
heterozygotes to determine if the R369H mutation causes dominant defects in muscle function. 
Heterozygous lines (L1-L3) display significant reductions in flight ability compared to controls at 
3 weeks of age (4.35 ± 0.20, 3.48 ± 0.21, and 4.04 ± 0.17 vs. 4.91 ± 0.15 A.U.; p= 0.0243, 
p<0.0001, and p<0.0001) (Fig. 5.7B), suggesting that the detrimental effects of the mutation on 
muscle function are dominant. 
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Figure 5.6- ATPase activity of R369H myosin 
Full-length myosin isolated from IFMs of R369H lines and wild-type transgenic controls 
(PwMhc2) was assessed for the following ATPase parameters: A) Basal Mg-ATPase activity, B) 
Ca-ATPase activity, C) Vmax of actin-activated Mg-ATPase, and D) actin affinity relative to 
ATPase (Km). E) To determine actin-activated activity, Mg2+ basal ATPase activities were 
subtracted from measured ATPase values without actin and over increasing concentrations of 
F-actin. Values were fit with the Michaelis-Menten equation to determine the Vmax and Km. Data 
are reported as mean ± SD. Statistical significance was determined using Student’s t-tests (ns= 
not significant). 
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Figure 5.7- Flight abilities of R369H mutant lines 
Homozygous (A) and heterozygous (B) R369H mutant lines (L1, L2, and L3) were crossed into 
a Mhc10 (myosin-null in IFMs and jump muscles) or Mhc10/+ background, respectively. Flight 
index was calculated as 6*U/(# flies) +4*H/(# flies) +2*D/(# flies) +0*N/(# flies) where each fly 
was assigned a score for flight upward (U), horizontally (H), downward (D) or the inability to fly 
(N). Values represent mean ± S.E.M. A total of N>100 flies were tested for each line/age. A) Full 
genotypes of homozygotes are shown in parenthesis: R369H lines (Mhc10/Mhc10; 
P[R369H]/P[R369H]); PwMhc2 transgenic controls (P[PwMhc2]/P[PwMhc2]; Mhc10/Mhc10). A 
two-way ANOVA was employed to test if the effects of genotype and age were significant 
(****p<0.0001). B) Full genotypes of heterozygotes are shown in parenthesis, where “-“ 
indicates that no P element is present on the homologous chromosome: R369H/+ lines 
(Mhc10/+; P[R369H]/-); PwMhc2/+ transgenic controls (P[PwMhc2]/-; Mhc10/+). A one-way 
ANOVA was employed to determine statistical significance between genotypes (***p<0.001, 
****p<0.0001, and ns= non-significant difference compared to controls). 
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Mean jump distance was also reduced in all three homozygous mutant lines (L1, L2, and 
L3) compared to controls at ages 2-day (6.09 ± 0.14, 4.58 ± 0.14, and 4.56 ± 0.09 cm vs. 7.08 ± 
0.16 cm) and 1-week (6.24 ± 0.12, 5.60 ± 0.12, and 3.97 ± 0.11 cm vs. 7.89 ± 0.14 cm) (Fig. 
5.8). Two-way ANOVAs demonstrated significant differences between control and mutant lines 
(p<0.0001), while the effects of age as an independent factor were not statistically significant. 
Though there was a statistically significant interaction between age and genotype (p<0.0001), 
this could be explained by the increase in jump muscle function observed in controls with age, 
rather than a deterioration in muscle function with age in mutant lines. Jump muscle function did 
not worsen from 2-days to 1-week of age in two of the lines tested (L1 and L2), contrary to the 
progressive and rapid decline in muscle function observed in IFMs. 
5.3.5. Transmission electron microscopy of IFMs 
Transmission electron microscopy was performed on thin-sectioned IFMs from 3 week-
old R369H homozygous mutants and controls. Transverse sections of both mutants and 
controls displayed myofibrils with normal, rounded morphology (Fig. 5.9: A-B), and a normal 
double hexagonal array of thick and thin filaments (Fig. 5.9: C-D). In longitudinal sections, 
myofibrils displayed normal parallel organization (Fig. 5.10: A-B), and sarcomeres displayed 
normal organization with intact myofilaments (Fig. 5.10: C-D). Average inter-thick filament 
distances (Fig. 5.9E) and sarcomere lengths (Fig. 5.10E) did not differ between mutants and 
controls. Overall, IFM ultrastructure was not disrupted in R369H mutants, suggesting that flight 
impairment in these lines was not caused by defects in myofibrillar assembly or maintenance. 
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Figure 5.8- Jump abilities of R369H mutant lines 
Homozygous R369H mutant lines (L1, L2, and L3) were crossed into a Mhc10 (myosin-null in 
IFMs and jump muscles) background. The top 3 of 10 jump distances were reported, and a total 
of N=40 flies were tested per line/age. Full genotypes are shown in parenthesis: R369H lines 
(Mhc10/Mhc10; P[R369H]/P[R369H]); PwMhc2 transgenic controls (P[PwMhc2]/P[PwMhc2]; 
Mhc10/Mhc10). Values represent mean ± S.E.M. A two-way ANOVA was employed to test if the 
effects of genotype and age were significant (****p<0.0001).  
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Figure 5.9- Ultrastructure of R369H IFMs in transverse orientation 
Transmission electron micrographs of thin-sectioned indirect flight muscles (IFMs) in transverse 
orientation were obtained from 3 week-old homozygous PwMhc2 control or R369H mutant flies 
in a Mhc10 (myosin-null in IFMs and jump muscles) background. Full genotypes are shown in 
parenthesis: R369H lines (Mhc10/Mhc10; P[R369H]/P[R369H]); PwMhc2 transgenic controls 
(P[PwMhc2]/P[PwMhc2]; Mhc10/Mhc10). A-B) Low magnification images showing myofibrillar 
morphology. MF- myofibril, M- mitochondrion. Scale bar, 0.5 µm. C-D) High magnification 
images showing hexagonal array of thick and thin filaments. Scale bar, 0.1 µm. E) Inter-thick 
filament spacing averages were determined from micrographs using a custom-written Python 
script. Values represent mean ± SD. Statistical significance was determined using Student’s t-
tests (ns= not significant). 
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Figure 5.10- Ultrastructure of R369H IFMs in longitudinal orientation 
Transmission electron micrographs of thin-sectioned indirect flight muscles (IFMs) in 
longitudinal orientation were obtained from 3 week-old homozygous PwMhc2 control or R369H 
mutant flies in a Mhc10 (myosin-null in IFMs and jump muscles) background. Full genotypes are 
shown in parenthesis: R369H lines (Mhc10/Mhc10; P[R369H]/P[R369H]); PwMhc2 transgenic 
controls (P[PwMhc2]/P[PwMhc2]; Mhc10/Mhc10). A-B) Low magnification images showing 
myofibrillar organization. MF- myofibril, M- mitochondrion. Scale bar, 2 μm. C-D) High 
magnification images showing sarcomeres bordered by Z-disks (arrowheads). Scale bar, 0.5 
μm. E) Average sarcomere lengths were determined from micrographs using Image-J software. 
Values represent mean ± SD. Statistical significance was determined using Student’s t-tests, 
where NS= non-significant difference compared to controls. 
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5.3.6. Cardiac physiological analysis 
To determine the effects of the R369H mutation on cardiac physiology, non His-tagged 
Mhc R369H transgenic flies were crossed into the Mhc1 myosin null background. Two copies of 
the Mhc R369H transgene rescued lethality of the Mhc1 homozygotes. Since a majority of 
homozygotes were not viable beyond the first 4 days of age, only young homozygotes were 
examined. Aged heterozygotes were viable, permitting the comparison of physiological 
parameters between young and aged heterozygotes. 
Young and aged R369H/+ flies showed no differences in diastolic (DD) and systolic (SD) 
diameters, as well as fractional shortening (FS) compared to controls (Fig. 5.11). Control flies 
displayed an age-associated increase in heart period (HP), which is the length of time required 
for the completion of a single diastolic and systolic event, from ages 4-days (0.542 ± 0.037 sec) 
and 3-weeks (Fig. 5.12) (1.392 ± 0.078 sec). Since R369H/+ lines did not display significant 
changes in HP with age, the HP durations were significantly lower in 3 week-old mutants 
relative to controls (0.665 ± 0.045 and 0.595 ± 0.045 sec vs. 1.392 ± 0.078 sec). Durations of DI 
were also lower relative to controls (0.452 ± 0.039 and 0.401 ± 0.040 sec vs. 1.166 ± 0.075 
sec). The effects of genotype (p<0.0001), age (p<0.0001), and an interaction effect (p<0.0001) 
contribute to differences in HP and DI between groups. Overall, aged R369H/+ mutants show 
elevated heart rhythm with no defects in contractility, suggesting that expression of the R369H 
mutation does not cause dominant reductions in cardiac output. 
To determine if expression of two copies of the mutant transgene causes more severe 
cardiac physiological abnormalities, homozygous R369H mutants were crossed into a 
Mhc1/Mhc1 myosin-null background. Both R369H homozygous lines tested showed no 
differences in physiological parameters related to cardiac diameters (i.e. DD, SD, and FS) or 
contractile dynamics (i.e. HP, DI, and SI) compared to controls (Fig. 5.13). 
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Figure 5.11- Cardiac physiological parameters of R369H/+ lines, Part I 
Cardiac diameters (A-B) and fractional shortening (C) values of 4 day-old or 3 week-old 
PwMhc2 control or mutant R369H heterozygous lines (L1 or L2) crossed into a heterozygous 
Mhc1-null background. Full genotypes are shown in parenthesis, where “-“ indicates there is no 
P element on the homologous chromosome: R369H/+ lines (Mhc1/+; P[R369H]/-); PwMhc2/+ 
transgenic controls (P[PwMhc2]/-; Mhc1/+). Values represent mean ± S.E.M. Two-way ANOVAs 
were employed to test if the effects of genotype and age were significant for each cardiac 
parameter investigated (****p<0.0001 and ns= non-significant). 
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Figure 5.12- Cardiac physiological parameters of R369H/+ lines, Part II 
Heart period (A), diastolic interval (B), and systolic interval (C) of 4 day-old or 3 week-old 
PwMhc2 control or mutant R369H heterozygous lines (L1 or L2) crossed into a heterozygous 
Mhc1-null background. Full genotypes are shown in parenthesis, where “-“ indicates there is no 
P element on the homologous chromosome: R369H/+ lines (Mhc1/+; P[R369H]/-); PwMhc2/+ 
transgenic controls (P[PwMhc2]/-; Mhc1/+). Values represent mean ± S.E.M. Two-way ANOVAs 
were employed to test if the effects of genotype and age were significant for each cardiac 
parameter investigated (****p<0.0001 and ns= non-significant). 
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Figure 5.13- Cardiac physiological parameters of R369H/R369H lines 
Cardiac dimensions (A-B), fractional shortening (C), and dynamics (D-F) of 4 day-old PwMhc2 
control or mutant R369H homozygous lines (L1 or L2) crossed into a homozygous Mhc1-null 
background. Full genotypes are shown in parenthesis: R369H lines (Mhc1/Mhc1; 
P[R369H]/P[R369H]); PwMhc2 transgenic controls (P[PwMhc2]/P[PwMhc2]; Mhc1/Mhc1). 
Values represent mean ± S.E.M. One-way ANOVAs determined statistical significance 
compared to controls, where ns= non-significant.  
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5.3.7. Cardiac ultrastructural analysis  
Transmission electron microscopy (TEM) was performed to determine if the R369H 
mutation affects cardiac ultrastructure. For both genotypes, myofibrils are oriented in a 
circumferential array around the heart tube and contain discontinuous Z-disks (Fig. 5.14: A-B, 
arrows), as standardly observed in this tissue.12,13,99-101 Mean cardiac thickness values on the 
dorsal-side and ventral-side do not differ in 4 day-old homozygous mutants compared to 
controls (Fig. 5.14: C-D). Overall, myofibrillar ultrastructural properties of cardiomyocytes are 
similar between 4 day-old R369H homozygous mutants and controls, suggesting that both 
myofibrillar assembly and maintenance are unaffected by the mutation.   
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Figure 5.14- Cardiac ultrastructure of R369H lines 
(A-B) Transmission electron micrographs of hearts of 4 day-old PwMhc2 control or mutant line 
R369H-L2 in a homozygous Mhc1-null background. Micrographs show transverse sections of 
the heart tube between the third and fourth sets of ostia. MF-myofibril. M- mitochondrion. VL- 
supportive ventral-longitudinal fibers. Scale bar, 0.5 µm. C-D) Cardiac thickness of dorsal-side 
(C) and ventral-side (D) areas of the heart were measured using ImageJ. Values represent 
mean ± standard deviation. Student’s t-tests determined statistical significance compared to 
controls, where ns= non-significant. 
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5.4. Discussion 
A human DCM patient was shown to have a de novo glutamine substitution at the 
conserved R369 residue of β-MyHC.117 This residue is located within loop 4 of myosin, within its 
upper 50 kDa subdomain.118,119 Previous cryo-electron microscopy (cryo-EM) work revealed that 
loop 4 is one of multiple surface loops at the actomyosin interface.31,32,52 Here we introduced a 
conservative R369H mutation into muscle myosin in the Drosophila model system to probe the 
role of loop 4 in regulating myosin function at the biochemical, ultrastructural and physiological 
levels.  
Previous reports support the hypothesis that loop 4 binds actin. Proteolytic cleavage of 
loop 4 reduced actin affinity >100-fold in bovine β-MyHC.120 Fluorescence and kinetic 
measurements revealed that the mutation of loop 4 residues to glycine reduced actin binding in 
Dictyostelium myosin II.118 Additionally, the mutation of a loop 4 G362 residue to alanine 
reduced actin affinity in chicken gizzard smooth muscle heavy meromyosin.119 An interaction 
between loop 4 and actin is further supported by cryo-EM work. A molecular dynamics 
simulation31 of a cryo-EM structure of actomyosin52 incorporating the myosin II25 and myosin 
V121 crystal structures revealed that the R371 residue, which is homologous to β-MyHC R369, 
forms an electrostatic interaction with D311 of actin in the rigor conformation.31 This model also 
revealed that myosin R371 forms hydrogen bonds with residues K328 and Q314 of actin. 
Additionally, a cryo-EM structure of actin-tropomyosin-myosin55 incorporating the crystal 
structure of Dictyostelium myosin-IE54 revealed direct binding of this residue to the SD3 subunit 
of actin in the rigor conformation.55 Finally, a cryo-EM structure of skeletal muscle myosin II 
bound to F-actin also supports a direct interaction between loop 4 and actin under rigor 
conditions.50  
Though the R369H mutation does not result in a charge change at that residue, it 
introduces a bulky imidazole ring which may sterically hinder an electrostatic interaction with 
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actin. We found that mutant myosin isolated from indirect flight muscles (IFMs) displayed 
reduced maximal binding to F-actin in vitro, suggesting that the R369 residue is important for 
actin interaction. Consistent with this hypothesis, fluorimetry experiments utilizing turkey gizzard 
smooth muscle myosin revealed that a mutation of the R370 residue (homologous to β-MyHC 
R369) to alanine weakened actin affinity.119  
During the crossbridge cycle, weak binding of myosin to actin triggers conformational 
changes that promote release of the products of ATP hydrolysis [inorganic phosphate (Pi), 
followed by ADP].77 When Pi is released, further intermolecular interactions at the actin interface 
stabilize a state in which myosin is strongly bound to actin.50,77,122 These events are coupled with 
two lever arm movements (powerstroke steps) that induce force generation. We observed no 
change in ATPase parameters of Drosophila MHC R369H relative to control MHC. Thus, it is 
possible that the transition from weak to strong actin binding is not disrupted by the mutation. 
The Km of actin affinity relative to ATPase is unchanged, consistent with our co-sedimentation 
data that the actin binding affinity (Kd) does not differ relative to controls. Since the Bmax of actin 
co-sedimentation is reduced in the mutant, it is possible that the mutation disrupts interactions 
important for stabilizing the strong actin binding state(s). In support of this hypothesis, a cryo-
EM model of actomyosin incorporating myosin crystal structures showed that loop 4 directly 
interacts with actin in the strongly-bound rigor state but not when myosin is weakly bound to 
actin.50 Future approaches can employ transient kinetics analyses to determine the exact 
chemomechanical steps affected by the R369H mutation. 
Since the R369H mutation reduces maximal actin binding, we hypothesized and that its 
expression in Drosophila would yield muscle functional deficits. R369H/+ flies displayed 
dominant reductions in flight ability at 3 weeks of age. Additionally, progressive defects in flight 
ability were observed in R369H/R369H flies from ages 2-day to 3-weeks. The causes of 
functional decline with age remain unknown. Ultrastructural properties of IFMs are normal in 3-
week-old R369H/R369H flies, suggesting that the severe reductions in muscle function at this 
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age are not caused by structural deterioration of myofibrils. However, age-related changes in 
gene expression81-83, protein expression84, as well as damage to lipids, proteins85,86, and 
organelles85 may play a role in exacerbating muscle functional deficits. Jump distances were 
also reduced in R369H/R369H flies, but did not decline with age. Overall, these data suggest 
that the R369 actin binding residue is critical for contractile function. In support of our 
hypothesis, the aforementioned human DCM patient harboring the R369Q mutation exhibited a 
deficit in fractional shortening (FS).117 
We assesed cardiac physiological parameters to determine whether R369H/+ lines 
exhibit a dilated phenotype and fractional shortening deficit similar to a human DCM patient 
harboring a mutation at this residue117. Though cardiac diameters and FS were normal in 
R369H/+ flies, contractile dynamics were altered in aged flies. An age-associated increase in 
heart period (i.e. decrease in heart rate) was observed in PwMhc2/+ controls from ages 4 days 
to 3 weeks. Similarly, age-associated reductions in heart rate were previously reported in older 
flies and were linked to impaired relaxation caused by a longer Ca2+ decay time105 or 
electrophysiological defects.107 It is also possible that altered expression of genes controlling 
cardiac ion channel function106, metabolism82,108, protein synthesis83, and protein folding83 may 
further influence heart rate decline with age. In contrast to controls, heart period did not change 
with age in R369H/+ flies. Thus, heart period was significantly lower in aged mutant hearts, 
which was associated with reduced diastolic intervals. Since contractility was not altered, the 
enhanced rhythmicity in R369H/+ flies increased cardiac output. It is possible that R369H/+ flies 
compensate for contractile deficits during development or cell stressors by altering one or more 
gene expression pathways that preserve cardiac output. For R369H/R369H homozygous flies at 
4 days of age, cardiac physiological and ultrastructural parameters did not differ compared to 
controls. Aged R369H/R369H lines were not viable in the Mhc1/Mhc1 myosin-null background, 
and were thus not examined. Overall, cardiac physiological parameters were mildly affected by 
the R369H mutation and did not reveal a DCM phenotype. Since the mutation does not 
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introduce a charge change, it is not surprising that its effects in Drosophila hearts are mild 
compared to the severe DCM phenotype in a human R369Q/+ patient. Interestingly, in 
Drosophila, the effects of the mutation are more severe in skeletal muscles compared to cardiac 
muscle, which may arise from differences in the amino acid backbone of the myosin isoforms or 
muscle physiological properties. 
In summary, we exploited the Drosophila model system to elucidate the importance of a 
conserved actin binding residue. We found that a conservative R369H mutation at this residue 
impairs maximal actin binding and reduces skeletal muscle function. A better understanding of 
the intermolecular interactions between myosin and actin may yield insight into the mechanistic 
basis for cardiomyopathies caused by impaired actomyosin binding. 
Chapter 5, in full, contains unpublished material coauthored by Trujillo, Adriana S.; Hsu, 
Karen; Viswanathan, Meera; Cammarato, Anthony R.; Bernstein, Sanford I. The dissertation 
author was the primary investigator and author of this chapter. 
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